 
 
 
 
Clinical Investigational Plan  
 
LIBERATE:  
A Clinical Evaluation of the Ecl ipse™ System, a Vaginal 
Bowel Control (VBC) Therapy  for Fecal Incont inence in 
Women  
 
Protocol : CA00 5 
Revision: D 
Date:  09 Feb 2017  
 
 
 
  
 
 
 
Study Sponsor:  
Pelvalon , Inc.  
[ADDRESS_971357] PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 1 of 58 
 
   
 
LIBERATE Protocol Synopsis  
Study 
Objective  To evaluate the durability of the safety and e ffectiveness of the Eclipse ™ System after 
[ADDRESS_971358] control, open label clinical trial  
Sites / 
Subjects  Up to  150 treatment -eligible subjects  may be enrolled into  the 12 month Treatment 
Period at up to 15  clinical sites in the [LOCATION_002]  
Study 
Population  Adult f emale s diagnosed with fecal incontinence  (FI) 
Study  
Duration  Screening Period : 5 - 7 weeks*  
Treatment Period : 12 months  
* Screening may be extended by [CONTACT_204180] 6 weeks to allow for  estrogen  pre-
treatment, if required  
Primary 
Endpoint The proportion of treatment responders, defined as a ≥ 50% reduction in the average 
number of FI epi[INVESTIGATOR_161594], as compared to baseline, at the 3 month time point  
in the ITT population   
Secondary 
Endpoints  
 1. Proportion of treatment responders at the  3, 6 and 12 month time points in the per 
protocol (PP) population 
2. Change from baseline in mean scores on subject -reported outcomes related to 
symptoms and quality of life as reported by [CONTACT_99894]. Mark’s (Vaizey) Incontinence 
Severity Score,  and FI Quality of Life (FIQOL) 
3. Patient Global Impression of Improvement (PGI -I) scores  at the 3, 6, 9 and 12 
month  time point s 
Safety 
Endpoint  Safety  of the Eclipse System is  assessed by [CONTACT_713618] -related (Eclipse 
System) adverse events , and device -related serious adverse events . 
Subgroup 
Analyses  < 65 years of age versus ≥ 65 years of age  
Inclusions :
General  
Eligibility  
Criteria  1. Female sex  
2. Age [ADDRESS_971359] can read, write and communicate fluently in English (the study diaries, 
questionnaires and instructions are only provided in English)  
6. Subject willing and able to comply with visit schedule  
7. Subject is able to physically manage the insertion and removal  of the Insert1 
Exclusions: 
Pregnancy 
Exclusion 
Criteria  8. Vaginal childbirth within the last [ADDRESS_971360] or,  if at risk of pregnancy (i.e. of childbearing potential), 
does not have a documented method of birth control . 
Exclusions: 
Physical / 
Pelvic 
Exam 
Criteria  
 11. Presence of fecal impaction on pelvic exam  [ADDRESS_971361] PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 2 of 58 
 
   
 
Exclusions: 
Current / 
Prior FI 
Treatments 
 16. Supervised  anal sphincter exercises/pelvic floor muscle training with or without 
biofeedback within the last 3 months and unwillingness to abstain from such for 
duration of study participation  
17. Use of home e- stim devices to stimulate pelvic floor muscles and unwillin gness to 
abstain from such use for duration of study participation 
18. Percutaneous Tibial Nerve Stimulation (PTNS)  treatment within the last 3 months 
and unwillingness to abstain from such for duration of study participation  
19. Injectable bulking agents (e.g. Solesta®)  for treatment of FI within the last 3 
months and unwillingness to abstain from such for duration of study participation  
20. Current sacral nerve stimulator (SNS) implant (Interstim®)  used  within the last [ADDRESS_971362]  be documented evidence that the 
device has been turned "off" for the past [ADDRESS_971363] use of the Eclipse System , its safety or effectiveness, or 
otherwise confound the results of this study  
Exclusions: 
Prior 
Surgeries  
 23. History of surgical diversion or removal of any portion of the bowel, except 
appendectomy or cholecystectomy  
24. History of bariatric surgery  
25. Hysterectomy within the last [ADDRESS_971364] 6 months  
27. Any history of reconstructive mesh surgery for pelvic organ prolapse or FI (mesh mid urethral slings are allowed)  
28. Urinary incontinence surgical procedure within past 6 months  
29. Colorectal/anal surgery such as rectopexy, sphincteroplasty, graciloplasty within 
the last 12 months  
Exclusions: 
Concurrent Medical 
Conditions  
 
 
 
 
  
 
  
 
 
  
 
 
 
 
  
 
 
 30. Chronic (greater than 6 months) abdominal pain in the absence of diarrhea  
31. Inflammatory bowel disease (IBD) such as Crohn’s Disease or Ulcerative Colitis  
32. Grade III or IV hemorrhoids  
33. Congenital anorectal malformation 
34. Chronic watery diarrhea (3 or more loose stools per day for 4 weeks or more) 
unmanageable by [CONTACT_713619]  
35. Laxative use as primary cause of FI  
36. Chroni c (greater than 3 months) fecal impaction requiring ongoing treatment   
37. Rectal prolapse (mucosal or full thickness)  
38. Chronic (greater than 6 months) rectal, anal or pelvic pain  
39. History of chronic or recurrent UTIs ([ADDRESS_971365] year)  
40. History of chronic or recurrent vaginal infections (4 or more per year) within the 
past year  
41. Any pelvic organ prolapse that extends beyond the plane of the hymen  
42. Concurrent use of an intra- vaginal pessary or other device that would interfere 
with the Eclipse™ Insert placement or wearing  
43. Presence of any urogenital or colorectal fistula involving the vagina, history of a 
recurrent fistula, or history of a prior failed or complicated fistula repair . A remote 
history (≥ 12 months ) of a single, well -healed fistula repair is allowed.    
44. Anal or pelvic (colorectal  or genitourinary ) malignancy within past five years  
45. History of pelvic irradiation for cancer  
46. Life expectancy of less than three years  
 
 
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 3 of 58 
 
   
 
Exclusions: 
Concurrent 
Medical 
Conditions  
(cont.) 
 47. Uncontrolled and complicated autoimmune or inflammatory disorder such as 
Systemic Lupus Erythematosus , Sjogren’s Syndrome, Rheumatoid Arthritis, or 
AIDS, that could have a confounding effect on FI severity or frequency during a 
yearlong study participation  
48. Neurological disorders known to affect bowel continence, such as advanced 
Multiple Sclerosis or Parkinson’s disease  
49. Subject has an unstable condition (e.g. psychiatric disorder, recent history of 
substance abuse) or otherwise thought to be unreliable or incapable of complying with the requirements of the study protocol   
50. Any other significant medical condition or lifestyle factor or confounder that the investigator believes would interfere with study participation and/or increase 
subject risk or interpretat ion of the primary or secondary endpoints  
Inclusions : 
Baseline 
Diary 51. At least [ADDRESS_971366] 12 out of 14 consecutive days of diary data recorded on the Baseline Diary
1 
Inclusions : 
Device 
Fitting  53. Successful fitting of the Trial Insert, i.e. device is both stable and comfortable 
while wearing [ADDRESS_971367] is able to physically manage the insertion and removal of the Insert 1 
Inclusions : 
Test Diary  
 55. Subject attains a 50% reduction or more in the number of FI epi[INVESTIGATOR_713578] 2- week Fitting Period compared to their 2- week 
Baseline Period. [ADDRESS_971368] PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 4 of 58 
 
   
 
Table of Contents  
 
1 Background  ..................................................................................................................................... 7 
1.1 Epi[INVESTIGATOR_713579]  .............................................................................................................................................................. 7 
1.2 Causes of FI  ........................................................................................................................................................................  7 
1.3 Availabl e Treatments ................................ ................................ ........................................................................................... 7 
1.4 Description of the Eclipse System  ....................................................................................................................................... 8 
1.4.1 Overview  ...............................................................................................................................................................................................8  
1.4.2 The Sizing Kit  ........................................................................................................................................................................................8  
1.4.3 The Trial Insert  ......................................................................................................................................................................................8  
1.4.4 The Eclipse Insert  .................................................................................................................................................................................8  
1.4.5 The Pump  ..............................................................................................................................................................................................9  
1.5 Mechanism of Action of the Eclipse System  ........................................................................................................................  9 
1.6 Prior Investigations  ............................................................................................................................................................ 11 
1.6.1 Feasibility Studies  .............................................................................................................................................................................. 11 
1.6.2 LIFE Pi[INVESTIGATOR_112688]  .............................................................................................................................................................................. 11 
1.7 Rationale for this Trial  ....................................................................................................................................................... 12 
1.8 Regulatory Status of the Eclipse System  ........................................................................................................................... 12 
1.9 Indications for Use  ............................................................................................................................................................ 12 
2 Study Description  ......................................................................................................................... 12 
2.1 Design............................................................................................................................................................................... 12 
2.2 Target Population  ................................ .............................................................................................................................. 12 
2.3 Recruitment  ................................ ................................ ....................................................................................................... 15 
2.4 Schedule of Events  ........................................................................................................................................................... 15 
2.5 Visit Schedule  ................................ ................................................................................................................................... 16 
2.6 Screening Period  ................................ ...............................................................................................................................  16 
2.6.1 Pre-Screening  .................................................................................................................................................................................... 16 
2.6.2 Visit 1 -  Baseline Visit  ......................................................................................................................................................................... 16 
2.6.3 Visit 2 -  Initial Fitting Visit -  14 days ( -2/+7 days ) from Baseline Visit  ............................................................................................... [ADDRESS_971369] (After Initial Fitting Visit)  ..................................................................................................................................... 19 
2.6.5 Visit 2a / 2b –  Repeat Fitting Visits (Optional) –  7 days ( -5/+7 days) from the Initial Fitting Visit  ..................................................... [ADDRESS_971370] (After Repeat Fitting Visits)  ................................................................................................................................ 20 
2.6.7 Visit 3 -  Fit Confirmation Visit -  7 days ( -5/+7da ys) from the final Fitting Visit  .................................................................................. 20 
2.6.8 Visit 4 – Treatment Eligibility Visit - 14 days ( -2/+7 days) after Visit 3  .............................................................................................. 21 
2.7 Treatment Period  ................................ .............................................................................................................................. 22 
2.7.1 Telephone Contacts (Between Visit 4 and Visit 5)  ............................................................................................................................ 22 
2.7.2 Visit 5 – 3 Months (± 2 weeks) after Visit 4  ........................................................................................................................................ 23 
2.7.3 Telephone Contacts (Between Visit 5 and Visi t 6) ............................................................................................................................ 23 
2.7.4 Visit 6 – 6 Months (± 2 weeks) after Visit 4  ........................................................................................................................................ 23 
2.7.5 Telephone Contacts (Between Visit 6 and Visit 7)  ............................................................................................................................ 24 
2.7.6 Visit 7 – 9 Months (± 2 weeks) after Visit 4  ........................................................................................................................................ 24 
2.7.7 Telephone Contacts (Between Visit 7 and Visit 8)  ............................................................................................................................ 24 
2.7.8 Visit 8 – 12 Months (± 2 weeks) af ter Visit [ADDRESS_971371]. Mark’s (Vaizey) Incontinence Severity Score  ............................................................................................................................... [ADDRESS_971372] Non -conformities and/or User Feedback  ............................................................................................................................. [ADDRESS_971373]  ............................................................................................................................ 45 
9 Appendices  .................................................................................................................................... 48 
Appendix 1 –  Informed Consent Form Template  ................................ ........................................................................................... 49 
Appendix 2 –  FI Epi[INVESTIGATOR_713580]  ......................................................................................................................................  50 
Appendix 3 –  FIQOL Questionnaire ................................ .............................................................................................................. 51 
Appendix 4 –  PGI-I Questionnaire  ................................................................................................................................................ 52 
Appendix 5 –  Patient Goal Questionnaire ................................ ..................................................................................................... 53 
Appendix 6 -  Device Satisfaction Questionnaire  ................................ ........................................................................................... 54 
Appendix 7 –  FI Information Brochure ................................ ..........................................................................................................  55 
Appendix 8 –  Eclipse System Instructions for Use  ........................................................................................................................ 56 
Appendix 9 –  Eclipse System Use and Care Instructions for LIBERATE Study Subjects  ................................ .............................. 57 
Appendix 10 –  Cost Utilization Survey  ................................ ..........................................................................................................  [ADDRESS_971374] of Figure  
 Figure 1. Insert (inflated state)  ...................................................................................................................... 9
 
Figure 2. Pump .............................................................................................................................................. 9 
Figure 3. Insert; deflated (left), and inflated (right)  ...................................................................................... [ADDRESS_971375] PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 6 of 58 
 
   
 
1 Background  
1.1 Epi[INVESTIGATOR_713581] (FI), also referred to as loss of bowel control or accidental bowel leakage (ABL), 
is a debilitating condition and a significant unmet need in women’s health.  Recent studies of 
community -dwelling women in t he U.S. report prevalence rates of 12- 25%.1,2,3,4,[ADDRESS_971376] a history of damage to the pelvic region caused 
by [CONTACT_713620].  Damage can involve the internal and external anal sphincters, pelvic 
floor muscles, and associated nerves (e.g., pudendal nerve).  P uerperal damage to these structures 
may not mani fest until later in life , possibly due to age-related changes in rectal sensation, 
compliance, and volume, in addition to further weakening of the sphincters and pelvic floor muscles.  
Many women with FI have multiple defects in their continence system, making effective treatment 
particularly difficult.   
1.[ADDRESS_971377]  demonstrated varying 
degrees of effectiveness, ranging from 50- 90% for biofeedback in conjunction with other 
therapi[INVESTIGATOR_014] , 9,[ADDRESS_971378] been less than 40% and the pr ocedure is usually only 
applicable for certain, repairable sphincter defects.11  The implantable artificial bowel sphincter is a 
surgical device that gives the patient dynamic control of the opening and closing of the anorectal 
canal.12  This mechanism of dy namic control has shown a 42.6% effectiveness  rate, compared to 
49.3% for dynamic graciloplasty ; however, the high morbidity related to its invasive nature has greatly 
limited its applicability.13  Such surgical interventions also require inpatient hospi[INVESTIGATOR_713582].  Recently, sacral nerve stimulation (SNS) has been used to treat FI  with up to 
1. Varma MG, Brown JS, Creasman JM, et al. Fecal incontinence in females older than aged 40 years: who is at risk? Dis Colon 
Rectum 2006; 49: 841– 851. 
2. Bharucha AE, Zinsmeister AR, Locke GR, et al. Prevalence and burden of fecal incontinence: a population- based study in women. 
Gastroenterology 2005; 129: 42– 49. 
3. Boreham MK, Richter HE, Kenton KS, et al.. Anal incontinence in women presenting for gyneco logic care: prevalence, risk factors, 
and impact upon quality of life. Am J Obstet Gynecol 2005; 192: 1637– 1642.  
4. Brown HW et al. Factors Associated With Care Seeking Among Women With Accidental Bowel Leakage. Female Pelvic Med 
Reconstr Surg 2013;19: 66Y71 
5. Lawrence JM, Lukacz ES, Nager CW, et al. Prevalence and co- occurrence of pelvic floor disorders in community -dwelling women. 
Obstet Gynecol 2008; 111: 678– 685. 
6. Romano, Carlo Ratto, Giovanni B. Doglietto (ed). Fecal incontinence: diagnosis and treatment (1. Ed. ed.). Milan: Springer, 2007.  
7 Sun W, Donnelly TC. Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic 
diarrhea and faecal incontinence. Scand J Gastroenterol 1997;32:34– 8. 
[ADDRESS_971379] roenterology 2003;125:1320– 29. 
9 Norton C et al. Conservative Management of Fecal Incontinence in Adults. Committee of the International Consultation on 
Incontinence. Management of fecal incontinence in adults. Neuro- urol Urodyn 2010; 29(1):199- 206. 
10 Hayd en, D.M. et al. Fecal Incontinence: Etiology, Evaluation, and Treatment. Clin Colon Rectal Surg 2011; 24:64- 70. 
11 Gutierrez et al. Long- term results of anterior sphincteroplasty. Dis Colon and Rectum 2004; 47:727- 732. 
12 Wong et al. Dis Colon and Rectum 2002;45:1139  -1153.  
13 Belyaev, O, Muller, C. and Uhl, W. Neosphincter Surgery for Fecal Incontinence: A critical and Unbiased Review of the Relevant 
Literature. Surg Today  2006;36:295- 303. 
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 7 of 58 
                                                       
 
   
 
83% at [ADDRESS_971380] able bulking agents, such as dextranomer in 
stabilized hyaluronic acid  (Solesta™),  have been used to treat FI, with a  reported efficacy rate of 
52%.[ADDRESS_971381] FI  patients are 
resigned to copi[INVESTIGATOR_713583] . 
1.4 Description of the Eclipse System  
1.4.1  Overview  
The Eclipse System is a vaginal bowel control (VBC) therapy intended to provide bowel control for 
women with fecal incontinence.  Manufactured by [CONTACT_713621] , Inc.  (Sunnyvale, CA), i t is comprised of 
a non- surgical device  placed in the vagina (referred to as the “Eclipse Insert ”) and a pressure-
regulated pump which is used to inflate and deflate the Insert.  A  Sizin g Kit, for use during the fitting 
process , and an evaluation Insert (referred to as the Trial Insert) are also provided.   
1.4.2  The Sizing Kit 
The Sizing K it is a set of reusable fitting inserts  (Sizers) which consist of the same stainless steel 
base and medical grade silicone coating as the Eclipse Insert,  but without the balloon that is part of 
the Eclipse system .  These reusable Sizers  are available in the same base sizes as the Eclipse Insert, 
and can be reused after reprocessing in accordance with the Instructions for Use ( IFU)..  
1.4.[ADDRESS_971382].  The Trial Insert is composed of a base 
made of medical grade silicone, polycarbonate, and stainless steel, and a balloon made from medical 
grade silicone and polyurethane.  
The Trial Insert consists of base- balloon configurations sized exactly as the Eclipse Inserts are sized 
and is intended for short -term use ( 1-2 weeks ). This disposable Trial Insert allows the subject to try 
one or more Insert sizes (while keepi[INVESTIGATOR_007] a fecal incontinence epi[INVESTIGATOR_637855]) during the Fitting Period 
before qualifying for and committing to the year -long trial of th e Eclipse Insert.   
A silicone inflation tube connects to the balloon on one end, and to a self -closing luer valve  (Valve) 
and cap on the other end which extends outside of the subject’s vagina.  An optional extension tube 
can be added between the existing tube and the V alve to increase the length. T he Valve allow s the 
user to inflate or deflate the balloon with the Pump.  
1.4.4  The Eclipse Insert  
The Eclipse Insert and the Trial Insert look the same;  this Insert is  graphically depi[INVESTIGATOR_6517] 1 . 
The Eclipse Insert is provided as a non- sterile unit for use by a single patient and i s currently available 
in a range of base sizes with two (2)  different balloon sizes . It is composed of a base made of medical 
grade silicone and stainless steel, and a balloon made of medical grade silicone and polyurethane.  
14 Leroi et al.  Efficacy of sacral nerve stimulation for fecal inconti nence: results of a multi -center, double- blind crossover study.  
Annals of surgery, volume 242, number 5, November 2005.  
15 Wexner et al.  Sacral nerve stimulation for fecal incontinence: results of a 120- patient, prospective, multi -center study. Annals of 
surgery, volume 251, number 3, March 2010.  
16 Graf et al.  Efficacy of dextranomer in stabilised hyaluronic acid for treatm ent of faecal incontinence: a randomized, sham -
controlled trial.  Lancet 2011; 377: 997- 1003.  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 8 of 58 
                                                       
 
   
 
A silicone inflation tube connects to the balloon on one end, and to a self -closing luer valve  (Valve) 
and cap on the other end which extends outside of the subject’s vagina.  T he Valve allow s the user  
to inflate or deflate the balloon with the  Pump.  An optional extension tube can be added between the 
existing tube and the V alve to increase the length.  
 
Figure 1. Insert (inflated state) 
1.4.5  The Pump  
A pressure- regulated Pump ( Figure 2) is provided to inflate and deflate the Insert . The Pump  
connects  to the Insert via the V alve.  The Pump has two ends that connect to the Valve: one end for 
adding air  (labeled with a “+”)  and t he other end for removing air ( labeled with a “ -“).  Air is moved 
through the Pump by [CONTACT_713622].  During inflation, the Pump is squeezed seven to ten 
times.  S even pumpi[INVESTIGATOR_713584]. The balloon will not over -
inflate because any excess air is vented out by [CONTACT_713623]. When the balloon is fully inflated, the 
internal pressure is set to the venting pressure of the regulator.  Regulators are removable so that 
different balloon pressures can be achieved.  Regulators and pumps are also designed for single-
patient use only.  Three different Regulators are available that regulate the balloon pressures to within 
the values listed in Table 1.  The Pump is packaged without  a regulator attached.  The “Low” , 
“Medium”  and “ High” Regulators are shipped separately.  
 
 
Figure 2. Pump  
 
Table 1. Regulators and Associated Pressures  
 
Regulat or Pressure at Full 
Inflation (mmHg)  
Low 45-57 
Medium  70-92 
High 114-129 
1.5 Mechanism of Action of the Eclipse System  
The Insert (refers to both the Eclipse Insert  and the Trial Insert) is placed in a position similar to other 
vaginal devices, such as diaphragms, pessaries, and tampons, whose safety profiles are well -
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page [ADDRESS_971383] .   
The Insert is designed to restore bowel continence in women with FI by [CONTACT_713624], which is complex and multi -factorial. The 
Insert util izes the naturally overlappi[INVESTIGATOR_713585] (or allow) 
stool passage in a user -controlled manner. Though separated by [CONTACT_713625], much of the vagina and rectum effectively share the same spac e.  When the rectum fills with 
stool, it expands, taking up more of this shared space.  This is often palpable on a vaginal exam as 
the vagina conforms to the shape of the expanded rectum.  Similarly, when an object is placed in the 
vagina, it is often pal pable in the rectum.  The redundant nature of the vaginal tissue makes it naturally 
conformable without discomfort or strain.  The Insert  is designed such that when it is placed in the 
vagina and is in the  deflated state, the rectal space is not occupi[INVESTIGATOR_530], allowing stool to pass through 
normally (see Figure 3 , left). When the Insert is inflated, the vagina conforms around it, causing a 
reduction in rectal space, which h elps the patient prevent unwanted stool passage (see Figure 3 , 
right).   
In Figure 4 the Insert is shown in its deflated state. The base of the Insert is  flexible to allow for 
ease of insertion and removal, as shown in Figure 5.  
               
Figure 3. Insert; deflated (left), and inflated (right)  
 
  
Figure 4. Deflated balloon  Figure 5. Folded Insert  
17 Lone et al. A 5 year  prospective study of vaginal pessary use for pelvic organ prolapse.  Int J Gynecol Obstet. 114 (2011) 56- 59. 
18 Clemons et al.  Patient sat isfaction and changes in prolapse and urinary symptoms in women who were fitted successfully with a pessary for 
pelvic organ prolapse. Am J Obstet Gynecol (2004) 190, 1025 -9. 
19 Bash, et al.  Review of vaginal pessaries.  Obstetrical and Gynecological Survey (2000) 55, 7, p455- 460. 
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 10 of 58 
                                                       
 
   
 
1.6 Prior Investigations  
1.6.1  Feasibility Studies  
Two feasibility studies were initially conducted t o assess the fit and function of the Eclipse  System in 
female subjects . These studies were approved by [CONTACT_25733]’s Institutional Review Board (IRB) as 
non-significant risk  (NSR)  device investigations . In total, 86 subjects were fit with the Insert who wore 
it for up to 3 months.  There were  9 device- related adverse events  reported, n one of which  were  
classified as  serious or unanticipated and all were mild (minor bleeding/lacerations from 
insertion/removal (3) or minor ecchymosis (6)) and all resolved quickly without medical intervention 
other than vaginal estrogen cream .  Subjects  in these studies demonstrated a positive response to 
the impact of the Eclipse  System  on their FI  symptom s.   
1.6.2  LIFE Pi[INVESTIGATOR_713586] (Protocol CA003)  was a multi- center,  prospective, open label clinical trial  conducted 
at six (6) centers in the [LOCATION_002] . As with the prior studies, a ll IRBs approved the trial as an NSR 
investigation. Furthermore, FDA is aware that this and the prior feasiblity studies were conducted as 
NSR investigations and did not object to this categorizatoin. The objective of this pi[INVESTIGATOR_713587] I ncontinence  
(FI) in adult women.     
A total of [ADDRESS_971384] 2012 and 
October 2013.  Subjects were required to experience ≥ 4 fecal incontinence epi[INVESTIGATOR_51953] a 2 week 
baseline diary assessment to qualify for participation.  Sixty -one (61) subjects met all study eligibility 
criteria and entered the 1 month Treatment Peri od to make up the Intent to Treat Cohort.  Fifty-six 
(56) subjects completed the 1 month Treatment Period without major protocol deviations to ma ke up 
the Per Protocol Cohort.  
The primary endpoint was the percent change in the number of epi[INVESTIGATOR_713588] 2- week assessment period (Treatment Period) as compared to the 
baseline 2- week assessment period.   Clinical effectiveness of the Eclipse  System (study success) 
was defined as occurring when at least 40% of the Intent to Treat Cohort demonstrated at least a 
50% decrease in the number of FI epi[INVESTIGATOR_1841] (recorded in a 2- week patient diary ) after 1 month of 
treatment with the device as compared to the number of FI epi[INVESTIGATOR_713589].  
Secondary endpoints were reduction in the number of incontinent days  while wearing the device and 
adverse events.  Other endpoints included symptom improvement measured by [CONTACT_713626] (FIQOL), Modified Manchester Health Questionn aire (MMHQ), and 
Patient Global Impression of Improvement (PGI -I).  
At 1 month, 78.7% of the ITT Cohort (95% CI, 66- 88%, p<0.0001) met the success criterion; 85.7% 
(95% CI, 74-94%, p<0.0001) met the success criteri on in the Per Protocol  analysis and 85.7% of 
participants considered their bowel symptoms "very much" or "much better". There was significant 
improvement in all FIQOL (all p<0.001) and MMHQ (all p≤0.007 ) subscales .  
There were no serious device- related adverse events  reported in the trial.  Two (2 ) SAEs were 
reported, neither of which was related to the study device, a fractured fibula and flu symptoms requiring hospi[INVESTIGATOR_059].  Among the 117 subjects in the Safety Cohort, 93 AEs in 61 subjects were reported as device- related  / possibly device- related, and another 26 AEs were reported in 21 subjects 
as not  / unlikely  device -related.   All device- related AEs were mild (78%) or moderate (22%) and none 
required any significant intervention ( defined as "i ntervention to prevent permanent impairment / 
damage" per the AE CRF).  No device- related AEs required surgical treatment to resolve, and only [ADDRESS_971385] PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 11 of 58 
 
   
 
required medical intervention:  topi[INVESTIGATOR_713590] a topi[INVESTIGATOR_713591]. Modification to pre-existing Estrace  usage was also required in some subjects .  
1.7 Rationale for this Trial  
The previous LIFE Study assessed safety and effectiveness of the Eclipse System ( including the 
Eclipse Insert and Pump) after [ADDRESS_971386] and an acceptable safety profile between  1 and 3 months it 
is expected that use of the device between 3 and  12 months will demonstrate a similar safety and 
effectiveness profile thr oughout the duration of use.  
1.8 Regulatory Status  of the Eclipse System  
The Eclipse System received marketing clearance from the U.S. Food and Drug Adm inistration (FDA) 
on November 12, 2015. . 
1.[ADDRESS_971387] previously 
attempted/failed other treatment methods . Note that final eligibility for enrollment into the Treatment 
Period involves several screening assessments .  It is anticipated that up to [ADDRESS_971388] of Inclusion and Exclusion Criteria  
Inclusions : 
General  
Eligibility  
Criteria  1. Female sex  
2. Age [ADDRESS_971389] can read, write and communicate fluently in English (the study diaries, 
questionnaires and instructions are only provided in English)  
6. Subject willing and able to comply with visit schedule  
7. Subject is able to physically manage the insertion and removal  of the Insert1 
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 12 of 58 
 
   
 
Exclusions: 
Pregnancy 
Exclusion 
Criteria  8. Vaginal childbirth within the last [ADDRESS_971390] or,  if at risk of pregnancy (i.e. of chi ldbearing potential), 
does not have a documented method of birth control . 
Exclusions: 
Physical / 
Pelvic 
Exam 
Criteria  
 11. Presence of fecal impaction on pelvic exam  [ADDRESS_971391] infection requiring treatment 3 
Exclusions: 
Current / 
Prior FI Treatments 
 16. Supervised  anal sphincter exercises/pelvic floor muscle training with or without 
biofeedback within the last 3 months and unwillingness to abstain from such for 
duration of study participation  
17. Use of home e- stim devices to stimulate pelvic floor muscles and unwillingness to 
abstain from such use for duration of study participation 
18. Percutaneous Tibial Nerve Stimulation (PTNS)  treatment within the last 3 months 
and unwillingness to abstain from such for duration of study participation  
19. Injectable bulking agents (e.g. Solesta®)  for treatment of FI within the last 3 
months and unwillingness to abstain from such for duration of study participation  
20. Current  sacral nerve stimulator (SNS) implant (Interstim®)  used  within the last  [ADDRESS_971392] be documented evidence that the 
device has been turned "off" for the past [ADDRESS_971393] use of the Eclipse System , its safety or effectiveness, or 
otherwise confound the results of this study  
Exclusions: 
Prior Surgeries  
 23. History of surgical diversion or removal of any portion of the bowel, except 
appendectomy or cholecystectomy  
24. History of bariatric surgery  
25. Hysterectomy within the last [ADDRESS_971394] 6 months  
27. Any history of reconstructive mesh surgery for pelvic organ prolapse or FI (mesh mid urethral slings are allowed)  
28. Urinary incontinence surgical procedure within past 6 months  
29. Colorectal/anal surgery such as rectopexy, sphincteroplasty, graciloplasty within  
the last [ADDRESS_971395] PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 13 of 58 
 
   
 
Exclusions: 
Concurrent 
Medical 
Conditions  
 30. Chronic (greater than 6 months) abdominal pain in the absence of diarrhea  
31. Inflammatory bowel disease (IBD) such as Crohn’s Disease or Ulcerative Colitis  
32. Grade III or IV hemorrhoids  
33. Congenital anorectal malformation 
34. Chronic watery diarrhea (3 or more loose stools per day for 4 weeks or more) 
unmanageable by [CONTACT_713619]  
35. Laxative use as primary cause of FI  
36. Chronic (greater than 3 months) fecal impaction requiring ongoing treatment   
37. Rectal prolapse (mucosal or full thickness)  
38. Chronic (greater than 6 months) rectal, anal or pelvic pain  
39. History of chronic or recurrent UTIs ([ADDRESS_971396] year)  
40. History of chronic or recurrent vaginal infections (4 or more per year) within the 
last year  
41. Any pelvic organ prolapse that extends beyond the plane of the hymen  
42. Concurrent use of an intra- vaginal pessary or other device that would interfere 
with the Eclipse™ Insert placement or wearing  
43. Presence of any urogenital or colorectal fistula involving the vagina, history of a 
recurrent fistula, or history of a prior failed or complicated fistula repai r. A remote 
history (≥ 12 months) of a single, well -healed fistula repair is allowed.   
44. Anal or pelvic (colorectal  or genitourinary ) malignancy within past five years  
45. History of pelvic irradiation for cancer  
46. Life expectancy of less than three years  
47. Uncontrolled and complicated autoimmune or inflammatory disorder such as 
Systemic Lupus Erythematosus , Sjogren’s Syndrome, Rheumatoid Arthritis, or 
AIDS, that could have a confounding effect on FI severity or frequency during a 
yearlong study participation  
48. Neurological disorders known to affect bowel continence, such as advanced 
Multiple Sclerosis or Parkinson’s disease  
49. Subject has an unstable condition (e.g. psychiatric disorder, recent history of 
substance abuse) or otherwise thought to be unreliable or i ncapable of complying 
with the requirements of the study protocol   
50. Any other significant medical condition or lifestyle factor or confounder that the 
investigator believes would interfere with study participation and/or increase 
subject risk or interpreta tion of the primary or secondary endpoints  
Inclusions : 
Baseline 
Diary 51. At least [ADDRESS_971397] 12 out of 14 consecutive days of diary data recorded on the Baseline Diary
1 
Inclusions : 
Device Fitting  
 53. Successful fitting of the Trial Insert, i.e. device is both stable and comfortable 
while wearing [ADDRESS_971398] is able to physically manage the insertion and removal of the Insert 1 
Inclusions : 
Test Diary  
 55. Subject attains a 50% reduction or more in the number of FI epi[INVESTIGATOR_713578] 2- week Fitting Period compared to their 2- week 
Baseline Period. [ADDRESS_971399] Diary will be eligible for treatment. Each site is expected to 
contribute approximately 7- 25% of the total  treatment -eligible subjects unles s authori zed in writing to 
over-enroll by [CONTACT_1034]. Enrollment is competitive until overall enrollment target is reached or 
study termination by [CONTACT_1034] . 
2.4 Schedule of Events  
The scheduled assessments performed at each visit are shown in Table 3.  
Table 3. Schedule of Events  
Assessment  Screening Period  Treatment Period  
(± 2 weeks)┬  
V1 V2 V3 V4 V5 V
6 V7 V8 
Unscheduled  Visit  Baseline  
Fitting  Visits * 
Fit 
Conf irmation  
 Treatment  
Eligibility  
 
3 Months  
6 Months  
9 Months  
12 Months  / 
Study Exit  
Informed Consent  X         
Inclusion/Exclusion Criteria (pregnancy test  done at 
baseline only , if applicable ) X X X X      
Clean catch urine test to r/o UTI┼ X X┼        
Demographics & Medical history / FI brochure  X         
FI epi[INVESTIGATOR_713592]  X  X X X  X   
FI epi[INVESTIGATOR_713593] & reviewed   X  X X X  X  
Device fit check    X  X X X X X† 
Pelvic  exam (speculum & digital rectal exam ) X X X X X X X X†† X† 
AE and Con Med review ‡  X X X X X X X X 
St. Mark’s (Vaizey ) Incontinence Severity Score  and 
FIQOL  questionnaire  X    X X X X  
PGI-I questionnaire      X X X X  
Patient Goal questionnaire   X   X X X X  
Device Satisfaction  questionnaire      X X X X††  
Cost Utilization survey  X    X   X  
*Fitting visits are repeatable up to 2 more times for a maximum of 3 fitting visits total . 
┬Telephone follow -up calls are required in between each Treatment Visit.  
┼ If clean catch urine test is positive, the test must be repeated until either it, or a urine culture test, 
is negative before performing a Fitting Visit (V isit 2) 
 
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 15 of 58 
 
   
 
† If clinically indicated . 
‡ AEs recorded starting at  the first Fitting Visit (Visit 2); Con Meds recorded at baseline and 
reviewed / updated at every visit.  
†† A pelvic exam and Device Satisfaction questionnaire are required at all early study exit visits after 
the first Fitting Visit (Visit 2) . 
2.[ADDRESS_971400] has signed the informed consent form. It is anticipated that up to 25% 
of subjects screened will be disqualified due to not meeting the general or pelvic exam 
inclusion/exclusion criteria, and up to another 25% may fail to meet the baseline FI frequency criteria.  
2.6.[ADDRESS_971401] the Sponsor’s trial management team to discuss 
the possibility of a waiver. A written confirmation of a waiver must be maintained in the subject 
record and should be reported to the IRB, if required by [CONTACT_941] s ite’s IRB reporting requirements. Study 
waivers are intended to be used j udiciously by [CONTACT_713627] .  
The following tasks are completed at this visit:  
• Informed Consent obtained  
• Inclusion/Exclusion criteria reviewed  
• Presentation of FI informational brochure  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 16 of 58 
 
   
 
• Pregnancy test and confirmation of birth control method (if subject is at risk for pregnancy , 
e.g. of childbearing potential ) 
• Clean catch urine dipstick for leukocyte esterase or nitrites┼ 
• Demographics and Medical History (including baseline concomitant medications)  
• Pelvic exam (speculum and digital rectal exam)  
• St. Mark’s (Vaizey)  Incontinence Severity Score  
• FIQOL questionnaire  
• Cost Utilization survey  
• Two week FI Epi[INVESTIGATOR_637797] (Baseline Diary) dispensed  
 
┼ If subject is positive for leukocyte esterase  or nitrites by a clean catch urine dipstick test at 
baseline, they should be treated as clinically indicated (Note - this is standard of care treatment, 
not paid for by [CONTACT_1758]), and continue with screening. However, they must be negative by [CONTACT_713628] , or by a urine culture test,  at Visit [ADDRESS_971402] may be 
repeated at the treat ing investigator’s discretion.  
All subjects should be presented with an FI brochure, containing standardized general information 
about the diagnosis and treatment of Fecal Incontinence during  the Baseline Visit20 (Appendix 7). 
Dissemination of this informat ion is meant to standardize the instructions given to each potential 
subject regarding the maint enance  of healthy bowel habits.  
In addition , all potential subjects should be counse led to maintain their usual diet and bowel health 
regimen as  much as  possible for the duration of their participation in the trial.  They should also 
continue any medications already in use for management of bowel and vaginal health for the 
duration of their participation. These medications specifically include any intra- vaginal estrogen 
creams such as  Estrace ® or Premarin® , and any supplements or medications for fecal 
incontinence or bowel health, such as fiber , they are using at the time of the Baseline Visit . 
Please query subjects regarding any planned dental  or medical procedures  or travel  in the next 
several months and assess the impact on subject’s ability  to keep a representative bowel diary and  
to keep appointments during the screening p eriod (between Visit 1 and Visit 4).   
Subjects who are deemed eligible are counseled on proper FI Epi[INVESTIGATOR_1865] D iary completion, and 
should demonstrate a satisfactory understanding of how to complete each of the questions in the diary.  The subject is instructed to start the Baseline Diary within the next [ADDRESS_971403] passes the general  inclusion/exclusion criteria including the pelvic exam criteria, then 
they will be scheduled to return for the Initial Fitting Visit as soon as possible within 14 days (-2/+7 
days ) after their Baseline Visit .  
 
Until a site has been proctored,  at the disc retion of the Sponsor,  there will be an exception made 
to the 21- day maximum window  between Visits [ADDRESS_971404]  fitting visit  (Visit 2) without it being c onsidered a protocol deviation.   
A subject  who present s with vaginal atrophy on initial exam may be prescribed a vaginal estrogen 
cream such as Estrace®  or Premarin®  if not contraindicated, and after all risks and benefits have 
been discussed with the subject (refer to the prescribing i nformation of the relevant vaginal 
20 NIH Publication No. 13- 4866. Dec. 2012. Available online at http://www.niddk.nih.gov/health- information/health- topi[INVESTIGATOR_1102]/digestive-
diseases/fecal -incontinence/Documents/Fecal_Incontinence_508.pdf  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 17 of 58 
                                                       
 
   
 
estrogen cream).  Subject  shoul d return within the next 2 –  [ADDRESS_971405] to proceed safely and comfortably with 
fitting of a vaginal device.  
 
Note : The Baseline Diary should still be started within the next 14 days  after the initial Baseline 
Visit, r egardless of the length of time between the Baseline Visit (Visit 1) and the scheduled Initial 
Fitting Visit  (Visit 2) . However, subjects will be allowed to repeat (stop and restart) their Baseline 
diary if during the two weeks recorded there were unusual or exceptional circumstances outside of 
the subject’s control e.g. illness, injury, natural catastrophe, or family emergency. Only the repeat 
diary data will be used to qualify the subject at Visit 2. Both original and repeat diaries must be 
retained. Pelv alon should be notified immediately and the rationale for allowing a subject to repeat 
their diary provided. The case will be evaluated by [CONTACT_19305], and a documented 
written approval must be obtained prior to using the repeat diary to calcul ate the subject's eligibility 
at Visit 2.   
 
As per the study inclusion criteria, t he diary should span 14 consecutive days , with no more than 2 
missing days of data between Visit 1 and Visit 2.   
2.6.3  Visit 2 - Initial Fitting  Visit  - 14 days (-2/+7 days)  from Baseline Visit  
Subjects are first evaluated for the frequency of their FI epi[INVESTIGATOR_713594]- week  
Baseline Diary. The subject must have completed at least [ADDRESS_971406] 4 epi[INVESTIGATOR_713595] (not staining) on 
their Baseline Diary in order to continue in the trial. If either of these criteria are not met , then  the 
subject is exited from the trial as a screen failure.   
 
Partial days  of data entry  should be counted as full days for the purposes of calculating eligibility.  
If the subject continues to qualify for the study based on their FI frequency, they will be asked to 
undergo a pelvic exam and fitting with the Trial Insert .  
For subjects who pre viously failed any pelvic exam inclusion/exclusion criteria that allow re-
evaluation, their Initial Fitting Visit may be extended up to 6 weeks from the Baseline Visit (without 
being considered a protocol deviation). The  previously  failed inclusion/exclusi on criteria must be  
re-evaluated during the Initial Fitting Visit pelvic exam, and must be resolved in order for the subject 
to continue in the trial.  Otherwise , they are exited from the study as a screen failure.  
For subjects who were prescribed an estrogen regimen, if the clinician determines that the vaginal 
tissue has adequately responded to the vaginal estrogen cream and the subject is willing to 
continue the use of the estrogen cream throughout the remainder of their study participation, they 
may continue with the Initial Fitting Visit. Otherwise,  they are exited from the study as a screen 
failure.  
The following tasks are completed at this visit:  
• Inclusion/exclusion criteria reviewed  
• Baseline Diary reviewed  
• Patient Goal questionnaire – goal identifica tion 
• Pelvic exam (speculum and digital rectal exam)  
• Trial Insert fitting   
• AEs and Concomitant Medications reviewed  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page [ADDRESS_971407] cannot obtain a suitable fit 
during this Initial Fitting Visit and/or decides to withdraw , the subject is exited from the trial as a 
screen failure.  
Per the eligibility criteria, during the Fitting Visits the subject must demonstrate the ability to properl y 
insert and remove the Trial Insert and inflate and deflate the Insert as needed using the Pump.  
If the subject meets the Baseline Diary and Initial Fitting Visit criteria,  they are instructed on proper 
use and care of the Eclipse  System  (Appendix 9 ), and are scheduled for a Fit Confirmation Visit 
within 7 days (-5/+7 days ) from the Initial Fitting Visit.  
 
The follow up visit should be scheduled as close to [ADDRESS_971408] should be seen earlier 
in the window (as soon as possible) if t hey are experiencing signs of an improper fit (discomfort or 
lack of effectiveness) , a device -related  adverse event,  or any of the following:  
- Foul odor or excessive vaginal  discharge  
- Any difficulty urinating or defecating  
- Significant bleeding not associated with menstruation  
- Unusual pelvic pain or discomfort  
 
If the subject is a screen failure based on their Baseline Diary or pelvic exam findings , the subject 
will be exited from the study  without completing the Patient Goal questionnaire or Trial Insert fitting. 
If the subject is a screen failure based on unsuccessful Trial Insert fitting,  any AEs related to the 
Trial Insert fitting procedure must be reported.  
[IP_ADDRESS] Fitting Procedu re 
The fitting procedure should proceed in accordance with the Eclipse Sy stem Instructions for Use 
(IFU).  (Appendix 8).  
[IP_ADDRESS] Eclipse System Use and Care Instructions  
Upon successful fitting with the Trial Insert , a copy of the Eclipse System  Use and Care Instructions 
for LIBERATE Study Subjects  (Appendix 9) which apply to the Eclipse System  (including the 
Eclipse Insert , Trial Insert , and the Pump ) should be reviewed and given to the subject to take 
home with them.  
2.6.[ADDRESS_971409] (After Initial Fitting Visit)  
Within 2-[ADDRESS_971410] during this phone call .  
2.6.5  Visit 2a / 2b – Repeat Fitting Visits (Optional) – 7 days (-5/+7 days)  from the 
Initial Fitting Visit  
Evaluation of fit over multiple  visits is standard clinical practice for many vaginal devices as it is 
often difficult to determine if the device will remain stable and comfortable until the subject wears it 
during their routine daily activities. A subject may undergo refitting, resulting in being sent home 
with a different size of the Trial Insert, up to two more times after the Initial Fitting Visit (for a 
maximum of 3 F itting  Visits in total) before t hey either exit the trial as a screen failure, or enter the 
final phase of screening and complete a 2- week Test Diary while wearing the fitted device.  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page [ADDRESS_971411]’s verbal report at the telephone contact [CONTACT_713629] [ADDRESS_971412] may proceed 
straight to the Fit Confirmation Visit #3.  If a repeat fit ting is performed, the following tasks are 
completed:  
• Inclusion/exclusion criteria reviewed  
• Pelvic exam (speculum and digital rectal exam)  
• Insert fitting as per the Fitting Procedure in Appendix 8 
• AEs and Concomitant Medications reviewed  
• Device satisfactio n questionnaire, only if subject is being exited as a screen fail  
 
If a successful fit with the Trial Insert is determined by [CONTACT_713630], the subject 
is classified as a screen failure, and the Insert is removed . All remaining scheduled activities for 
Visit 2a / 2b  will still be  completed and the subject will be exited from the study.   
If a suitable fit is attained with a different sized Trial Insert , then  the subject is re-instructed on 
proper use and care of the Eclipse  System  (Appendix 9), and is scheduled for a  Fit Confirmation 
Visit within 7 days ( -5/+7 days) from the Repeat Fitting Visit.   
 
The follow up visit should be scheduled as close to [ADDRESS_971413] should be seen earlier 
in the window (as soon as possible) if they are experiencing signs of an improper fit (discomfort or 
lack of effectiveness) , a device -related  adverse event, or any of the following:  
 
- Foul odor or excess ive vaginal discharge  
- Any difficulty urinating or defecating  
- Significant bleeding not associated with menstruation  
- Unusual pelvic pain or discomfort  
2.6.[ADDRESS_971414] (After Repeat Fitting Visits)  
Telephone contact [CONTACT_713631] V isit (Section 2.6.4).  
2.6.7  Visit 3 - Fit Confirmation Visit - 7 days ( -5/+7days)  from the final Fitting Visit  
The subject is evaluated for a continued good fit of the Trial Insert, as described in Appendix 8 
and the following tasks are completed:  
• Pelvic exam (sp eculum and digital rectal exam)  
• AEs and Concomitant Medications reviewed  
• Device satisfaction questionnaire, only if subject is being exited as a screen fail  
• Two week FI Epi[INVESTIGATOR_1865] D iary (Test Diary) dispensed, only if subject continues to meet all 
eligibility criteria  
• Order the c orresponding Eclipse Insert , only if subject continues to meet all eligibility 
criteria  
 
If per clinician assessment during the pelvic exam a suitable fit wi th the Trial Insert is deemed to 
be unattainable, the subject is classified as a screen failure and the Insert is removed.  All other 
scheduled activities for Visit 3 will still be completed (excluding dispensing a Test Diary  and 
ordering the Eclipse Insert ) and the subject will be exited from the study.  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 20 of 58 
 
   
 
Based upon the fitting rate observed in the LIFE (CA003) Trial, it  is estimated that approximately  
24% of subjects who have an Initial Fitting Visit may be disqualified due to not achieving a stable 
and comfortable fit of the Insert.  This fitting rate is comparable to fitting rates obse rved with other 
vaginal devices.21, [ADDRESS_971415] is  re-instructed on proper use and care of the 
Eclipse  System (Appendix 9) and on the proper completion of the two week Test Diary, and is 
scheduled for their  final Treatment  Eligibility Visit within 14 days ( -2/+7days ) from the Fit 
Confirmation Visit .  
The subject is instructed to start the Test Diary within the next [ADDRESS_971416]’s mind.  If a subject is 
expecting her menstrual cycle to begin during the next [ADDRESS_971417] Diary by [CONTACT_713632] 
(without being considered a protocol deviation)  since  collection of efficacy data would be 
inappropriate during a period of time when the device is not being worn . The Test Diary should be 
started the day after menstruation ends.   
In additi on, subjects will be allowed to repeat (stop and restart) their Test diary if during the two 
weeks recorded there were unusual or exceptional circumstances outside of the subject’s control 
e.g. illness, injury, natural catastrophe, or family emergency. Onl y the repeat diary data will be used 
to qualify the subject at Visit 4. Both original and repeat diaries must be retained. Pelvalon should 
be notified immediately and the rationale for allowing a subject to repeat their diary provided. The 
case will be eva luated by [CONTACT_19305], and a documented written approval must be 
obtained prior to using the repeat diary to calculate the subject's eligibility at Visit 4.  
 
As per the study inclusion criteria, t he diary should span [ADDRESS_971418] Diary  data collection due to missing days of data, 
but the Treatment Eligibility Visit (Visit 4) may  be re- scheduled if interrupted by a menstrual cycle , 
illness, injury, natural catastrophe, or family emergency  to allow for 12 -14 days of diary data 
collection  (without it being considered a protocol deviation) .  
2.6.8  Visit 4 – Treatment Eligibility Visit  - 14 days ( -2/+7 days ) after Visit 3  
The following tasks are completed at this visit:  
• Two week Test Diary review  
• Pelvic exam (speculum and digital rectal exam)  
• AEs and Concomitant Medications reviewed  
• Device satisfaction questionnaire, only if subject is being exited as a screen fail  
• Two week FI Epi[INVESTIGATOR_637797] (Treatment Diary) dispensed (for use prior to the 3 month visit) , 
only if subject continues to meet all eligibility criteria  
• Eclipse Insert dispensed , only if subject continues to meet all eligibility criteria  
 
The Test Diary  is assessed for completeness and for the number of fecal incontinence epi[INVESTIGATOR_713596]. Subjects who  meet the Visit [ADDRESS_971419] Diary inclusion criteria by (a) recording 
[ADDRESS_971420] PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 21 of 58 
                                                       
 
   
 
a minimum of 12 out of 14 consecutive days of diary data and (b) achieving a 50% or greater 
reduction in the average number of FI epi[INVESTIGATOR_1841]  (major or minor soiling)  on their Test Diary 
compared to their Baseline Diary will be enrolled into the Treatment Period of  the study. Partial 
days  of data entry  should be counted as full days for the purposes of calculating eligibility.  
Subjects who do not meet the Visit [ADDRESS_971421] is classified as a screen failure, all other 
scheduled activities for Visit 4 will still be completed (except for dispensing a Treatment Diary  and 
the Eclipse Insert ) and the subject will be exited from the study.  
If the subject continues to meet all eligibility criteria, she will be given the same sized Eclipse 
Insert as the Trial Insert used during the Test Diary, and the used Trial Insert will be disposed of  
at the site , unless directed otherwise by [CONTACT_713633] a potential product 
malfunction associated with  the used Trial Insert, in which case it will be returned to the Sponsor 
for investigation.  The subject should continue to use the same Pump.  The subject is to be re-
counseled on the requirements of the Treatment Period of the protocol, on the proper use and 
care of the Eclipse System (Appendix 9), and on proper completion of the Treatment Diary.  
The subject is instructed to complete the Treatment Diary while wearing the Eclipse Insert for a 
consecutive 14 day (2 week) period just prior to the next scheduled visit  at 3 months ( ± 2 weeks ) 
after Visit [ADDRESS_971422] 2 weeks 
prior to the 3, 6 and 12 month visits.  There is no Treatment Diary required at the 9 month visit. Subjects will be instructed to complete the diary for 14 consecutive days while wearing the Eclipse 
Insert . The timing of the start and/or completion of the Treatment Diary may be adjusted by  [CONTACT_8622] 2 
weeks  (without being considered a protocol deviation)  if a subject’s menstrual cycle interrupts their 
wearing of  the Eclipse Insert  during the two- weeks when the Treatment Diary is scheduled, 
rendering assessment of effectiveness during this period of time inappropriate.   
In addition, subjects will be allowed to repeat (stop and restart) their Treatment D iary if the two 
weeks recorded were unusual or unrepresentative of their true condition due to  circumstances 
outside of their control e.g. illness, injury, natural catastrophe, or family emergency. Only the repeat 
diary data will be data entered. Both original and repeat diaries must be retained. Pelvalon should 
be notified immediately and the rati onale for allowing a subject to repeat their diary provided. The 
case will be evaluated by [CONTACT_19305], and a documented written approval must be 
obtained prior to using the repeat diary for data entry.   
If any subject arrives at a 3, 6, or [ADDRESS_971423] will undergo a pelvic exam at each visit in order to verify proper use of the Eclipse 
Insert  and adequate hygiene, as well as to assess any adverse events.  
2.7.1  Telephone Contacts (Between Visit 4 and Visit 5)  
The subject should be contact[CONTACT_713634] f or use, is not experiencing any technical or 
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 22 of 58 
 
   
 
medical problems while wearing the Eclipse Insert, and to remind her to complete the Treatment 
Diary at the required time.  
2.7.2  Visit 5 – 3 Months (±  2 weeks)  after Visit 4  
Subjects are evaluated for the frequency of  their FI epi[INVESTIGATOR_713597], and are evaluated for continued fit and safety of the Eclipse Insert.  
The following tasks are completed at this visit:  
• Two week Treatment Diary reviewed  
• St. Mark ’s (Vaizey ) Incontinence Severi ty Scor e calculated  
• FIQOL  questionnaire administered  
• PGI-I questionnaire administered  
• Patient Goal questionnaire administered  
• Cost Utilization survey administered  
• Device Satisfaction questionnaire administered  
• Pelvic exam (speculum and digital rectal exam)  
• AEs and Concomitant Medications reviewed  
• Two week Treatment Diary dispensed (for use prior to the 6 month visit)  
 
The subject is re- counsel ed on the requirements of the Treatment Period of the protocol, on the 
proper use and care of the Eclipse System (Appendix 9) and proper completion of the Treatment 
Diary.  
The subject is instructed to complete the Treatment Diary while wearing the Eclipse Insert for a 
consecutive 14- day (2 week) period just prior to the next scheduled visit.  
2.7.3  Telephone Contacts (Between Visit 5 and Visit 6)  
The subject should be contact[CONTACT_713635], is not experiencing any technical or 
medical problems while wearing the Ecl ipse Insert, and to remind her to complete the Treatment 
Diary at the required time.  
2.7.4  Visit 6 – 6 Months (± 2 weeks) after Visit 4  
Subjects are evaluated for the frequency of their FI epi[INVESTIGATOR_713598], and are evaluated f or continued fit and safety of the Eclipse Insert.  
The following tasks are completed at this visit:  
• Two week Treatment Diary reviewed  
• St. Mark ’s (Vaizey ) Incontinence Severity Scor e calculated  
• FIQOL  questionnaire administered  
• PGI-I questionnaire administer ed 
• Patient Goal questionnaire administered  
• Device Satisfaction questionnaire administered  
• Pelvic exam (speculum and digital rectal exam)  
• AEs and Concomitant Medications reviewed  
 
The subject is re- counseled on the requirements of the Treatment Period of the protocol, and on 
proper use and care of the Eclipse System (Appendix 9). A Treatment Diary is not dispensed at 
Visit [ADDRESS_971424] PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 23 of 58 
 
   
 
2.7.5  Telephone Contacts (Between Visit 6 and Visit 7)  
The subject should be contact[CONTACT_713636]- month 
intervals to ensure she is  following the instructions for use and is not experiencing any technical or 
medical problems while wearing the Eclipse Insert.  
2.7.6  Visit 7 – 9 Months (± 2 weeks) after Visit 4  
Subjects are evaluated for continued fit and safety of the Eclipse Insert.  
The following tasks are completed at this visit:  
• St. Mark ’s (Vaizey)  Incontinence Severity Score calculated  
• FIQOL  questionnaire administered  
• PGI-I questionnaire administered  
• Patient Goal questionnaire administered  
• Device Satisfaction questionnaire administered  
• Pelvic exam (speculum and digital rectal exam)  
• AEs and Concomitant Medications reviewed  
Two week Treatment Diary dispensed (for use prior to the 12 month v isit) 
 
The subject is re- counseled  on the requirements of the Treatment Period of the protocol, on 
proper use and care of the Eclipse System (Appendix 9) and proper completion of the Treatment 
Diary.  
The subject is instructed to complete the Treatment Diary while wearing the Eclipse Insert for a 
consecutive 14- day (2 week) period just prior to the next scheduled visit.  
2.7.7  Telephone Contacts (Between Visit 7 and Visit 8)  
The subject should be contact[CONTACT_713637] h 
intervals to ensure she is  following the instructions for use, is not experiencing any technical or 
medical problems while wearing the Eclipse Insert, and to remind her to complete the Treatment 
Diary at the required time.  
2.7.8  Visit 8 – 12 Months  (± 2 weeks) after Visit 4  
Subjects are evaluated for the frequency of their FI epi[INVESTIGATOR_713597], and for safety of the Eclipse Insert.  
The following tasks  are completed at this visit:  
• Two week Treatment Diary reviewed  
• St. Mark ’s (Vaizey ) Incontinence Severity Score calculated  
• FIQOL  questionnaire administered  
• PGI-I questionnaire administered  
• Patient Goal questionnaire administered  
• Cost Utilization survey administered  
• Device Satisfaction questionnaire administered  
• Pelvic exam (speculum and digital rectal exam)  
• AEs and Concomitant Medications reviewed  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page [ADDRESS_971425] medical interview 
and physical examination, including a pelvic examination  or Insert re -sizing , if appropriate.  All 
assessments, and any abnormal findings , including AEs and/or product malfunctions,  will be 
documented in the appropriate case report forms.  
2.8 Re-sizing  during Treatment Period  
If at any time during or after Visit 5 (the 3- month time point visit) , an Insert no longer fits appropriately 
as assessed by a clinician during a pelvic exam , re-sizing of the Insert may  be performed. The Insert 
may be re- sized  at the treatment visit or at an U nscheduled Visit in between T reatment Visits per the 
following steps :  
1. If changing to a different Sized Insert , use one or more of the Sizers  to determine the next 
appropriate sized  Trial Insert , and send the subject home with the Trial Insert . Complete a 
Fitting CRF , and order the corresponding Eclipse Insert from Pelvalon immediately so it arrives 
in time for the follow -up Fit Confirmation Visit.  Complete either the Treatment Pelvic Exam CRF 
or an Unscheduled Visit CRF, as appropriate.  
2. Schedule a follow up visit within 7 days (-5/+7 days ) to confirm the Trial Insert fit  is comfortable 
and stable by [CONTACT_183516].  The follow up visit should be scheduled as close to [ADDRESS_971426] should be seen earlier in the window (as soon as possible) if they are experiencing 
signs of an improper fit (discomfort or lack of effectiveness) , an adverse event  or any of  the 
following:  
 
- Foul odor or excessive vaginal discharge  
- Any difficulty urinating or defecating  
- Significant bleeding not associated with menstruation  
- Unusual pelvic pain or discomfort  
 
3. If successfully re -sized, dispose of the Trial Insert and dispense the same sized Eclipse Insert 
and instruct the subject to begin her next Treatment Diary as scheduled.  The start of the 
Treatment Diary should be delayed, if necessary,  so that it begins seven days or more after 
the newly sized Eclipse Insert is dispensed.  
4. Steps 1- [ADDRESS_971427]’s participation may be discontinued early for any of the following reasons:   
• Failure to meet screening eligibility criteria  at any time after Visit 2  
• Withdrawal of consent  
• Adverse event preventing further study participation  
• Investigator decision / determination that it is in the subject’s best interest  
• Termination of the study for any reason  
• Lost to follow -up: requires documentation of at least [ADDRESS_971428] by 
[CONTACT_17084]/or email, and a  certified letter (with request to return the investigational device)   
• Subjects who become pregnant will be discontinued from the trial  
 
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 25 of 58 
 
   
 
For all subjects who were fit with the Eclipse System at Visit 2 and exit the study prior to or at Visit 4 
(Treatment Eligibi lity Visit), AEs and ConMeds will be reviewed and a pelvic exam and the Device 
Satisfaction questionnaire  will be administered, as per Table 3.  
For subjects who exit the study after Visit 4 (Treatment Eligibility Visit) but before Visit 8 (12 Months) 
AEs and ConMeds will be reviewed, and a pelvic exam and all required questionnaires per Table 3  
will be administered.  
To compensate for time spent during study visits, subjects may receive compensation as detailed in 
the final IRB -approved consent form and as agreed upon by [CONTACT_713638].  
2.10 Questionnaires and Surveys  
2.10.1  FI Epi[INVESTIGATOR_713599] a  Diary ( Appendix 2 ) to record each bowel movement,  including the type 
of epi[INVESTIGATOR_1865] (normal bowel movement, staining, minor soiling or major soiling),  whether the bowel 
movement was “urgent” (yes or no) and the stool description according to the Bristol Stoo l Score  
(ranging from  1 “separate hard lumps” to  7 “liquid consistency with no solid pi[INVESTIGATOR_6928] ”). The Baseline  
Diary is dispensed at Visit 1 (Baseline Visit), the Test Diary is dispensed at Visit 3 (Fit Confirmation 
Visit), and the Treatment Diary is dispense d at Visit 4 (Final Eligibility Visit), and at the [ADDRESS_971429] is  wearing the Insert at the time of each recorded epi[INVESTIGATOR_1865].   
Only minor or major soiling are counted towards the number of FI epi[INVESTIGATOR_713600]- week diary 
period, used in the study endpoint analyses  (see Section 3.2).  
2.10.[ADDRESS_971430]. Mark ’s (Vaizey) Incontinence Severity Score  
The St. Mark’s  (Vaizey) Incontinence Severity Score is a measure of severity of FI symptoms, which 
has been shown to correlate with improvement in frequency of FI epi[INVESTIGATOR_713601]’ 
perceptions of relief. 23,24,25  This score reflects the severity of FI and ranges from 0 (complete 
continence) to 24 (complete incontinence) . The survey will be administered verbally to subjects by 
[CONTACT_713639] 1 (Baseline Visit), and at 3, 6, 9 and 12 months during the Treatment P eriod . 
2.10.3  Fecal Incontinence Quality of Life Questionnaire    
The Fecal Incontinence Quality of Life (FIQOL) scale ( Appendix 3) is a 41- item, validated 
questionnaire completed by [CONTACT_423]. 26  FIQOL has 4 subscales: lifestyle, copi[INVESTIGATOR_007]/behavior, 
depression/self -perception and embarrassment.  The FIQOL questionnaire w ill be completed by 
[CONTACT_147326] 1 (Baseline Visit) and at 3, 6, 9 and 12 months during the Treatment P eriod . 
2.10.4  PGI-I Questionnaire  
The Patient Global Impression of Improvement (PGI -I) (Appendix 4) is a validated global index 
that may be used to rate the response of a condition to a therapy on a scale from 1 ( Very much 
better ) to 7 ( Very much worse) . It is a simple, direct, easy to use scale that is intuitively 
23 Vaisey, CJ, et al Gut  1999;44:77- 80 doi:10.1136/gut.44.1.77  
24 Deutekom M, Terra MP, Dobben AC, Dijkgraaf MG, Felt -Bersma RJ, Stoker J, Bossuyt PM: Selecting an outcome measure for 
evaluating treatment in fecal incontinence.  Dis Colon Rectum  2005,  48:2294- 2301.  
[ADDRESS_971431]. Mark's incontinence score reflect patients' perceptions? A review of 390 patients.  Dis Colon Rectum. 2008 
Apr;51(4):436- 42 
26 Rockwood et al.  Fecal Incontinence Quality of Life Scale.  Dis Colon Rectum 2000;43:9- 16. 
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page [ADDRESS_971432] often used to assess the 
subjects’ response to various treatments for urinary incontinence.[ADDRESS_971433]’s 
response to  treatment with the Eclipse System for fecal incontinence.  The PGI -I questionnaire will 
be completed by [CONTACT_277935] 3, 6, 9 and 12 months during the Treatment P eriod . 
2.10.5  Patient Goal Questionnaire   
At the Visit 2 subjects will be asked to specify a single pat ient-centered goal describing what a 
successful improvement in FI symptoms would mean for them.  For example, they may identify 
“confidence in attending social events” or “ability to exercise without incontinence.”  At the 3, 6, 9 
and 12 month visits  subjects will rank how well they were able to meet their goal while wearing the 
Eclipse Insert  using a 7-point scale ( Appendix 5) ranging from “I have met and exceeded my goal”  
(best case) to “I have moved further away from my goal” (worst case). The patient goal categories  
are based on results from  a survey of women undergoing pel vic floor dysfunction surgery. [ADDRESS_971434] once with the Trial or Eclipse Insert will be asked to complete a Device 
Satisfaction Questionnaire  (Appendix 6). The questionnaire contains questions related to 
perceptions of device comfort, satisfaction with usage and features, and impact on daily activities.  
Subjects who Screen Fail but have been fit at least once with the Insert  will be asked to complete 
this questionnaire just prior to their study exit. Subjects who successfully enter the Treatment 
Period will be asked to complete this questionnaire at 3, 6, 9 and 12 months  during the Treatment 
Period (or at study exit if they end the ir participation in the trial early ).  
2.10.[ADDRESS_971435] Utilization survey ( Appendix 10 ) in order to capture the 
direct medical and non- medical (out of pocket) and indirect non- medical costs related to treat ing FI 
in the three months prior to  Visit 1 (Baseline Visit) and again at the [ADDRESS_971436] control, open- label, single -arm study to evaluate the 
durability of the safety and effectiveness of the Eclipse™ System after [ADDRESS_971437] as their own control. Subjects will be fitted, and refitted if necessary, with the Trial 
Insert during the Screening Period.  Subjects who successfully complete the Screening Period will 
be considered as treatment -eligible  and will be fitted with the Eclipse Insert and begin the 12 month 
Treat ment Period.  Subjects who do not successfully complete the Screening Period will be 
classified as screen fails and will not continue into the Treatment P eriod.  
27 Yalcin I, Bump R. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003;189:98- 101.  
28 Kathie L. Hullfish, Viktor E. Bovbjerg, Jennifer Gib son, William D. Steers  Patient -centered goals for pelvic floor dysfunction 
surgery: What is success, and is it achieved? American Journal of Obstetrics and Gynecology, Volume 187, Issue 1, July 2002, 
Pages 88- [ADDRESS_971438] PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 27 of 58 
                                                       
 
   
 
3.2 Derivations and Definitions  
The baseline period is the period prior to the Initial Fitting Visi t.  Results from this period, using 
either the Baseline Diary or assessments conducted at Visit 1, will be the baseline results.  
Change from baseline  is calculated as (visit result) –  (baseline result).  
Percent change from baseline  is calculated as 100*(c hange from baseline) / (baseline result).  
An FI epi[INVESTIGATOR_713602], but does not include staining alone, as 
recorded on Baseline Diary, Test Diary or Treatment Diaries , each defined as follows : 
- Staining : Stain of stool on undergarment, pad, clothing, or skin (does not count as an FI 
epi[INVESTIGATOR_1865]).  
- Minor soiling :  Stool leakage that is more than staining, but did not require an immediate 
change of undergarment, pad, or clothing (e.g. a pebble sized pi[INVESTIGATOR_713603]) .  
- Major soiling :  An accident  large enough to require an immediate change of 
undergarment, pad, or clothing (e.g. most of a bowel movement) .  
A bowel movement is defined as urgent if the subject  checks: “I had to rush to the restroom 
immediately. ” Note: “Urgent” can be marked regardless of whether you made it to the toilet in time 
(for a normal bowel movement) or not (resulting in leakage).”  
The following will be calculated for each diary period using the information entered in the FI 
Epi[INVESTIGATOR_713604] ( Baseline Diary, Test Diary, and Treatment Diaries ): 
Average number of FI epi[INVESTIGATOR_161594] : 7 * (# epi[INVESTIGATOR_1841]) / (# days of diary entry)  
Average number of FI days per week: 7 * (# of days with ≥ 1 FI epi[INVESTIGATOR_1865]) / (# days of diary entry)  
Screen Failure : A subject who does not successfully complete the Screening P eriod.  This could be 
due to failing any of the general inclusion/exclusion criteria such as age or FI frequency by [CONTACT_713640], unsuccessful fit ting (as determined before or at Visit 4), failure to record a 
minimum of 12 days of diary data after successful fitting (i.e. Test Diary), or failure to demonstrate a 
50% or greater reduction in the average number of FI epi[INVESTIGATOR_713605].  
Treatment -eligible Subject  (Enrolled) : A subject who successfully completes the Screening P eriod 
and enters the Treatment period is considered enrolled . This is defined as a subject having a 
confirmed successful fitting (as determined at Visit 3), having recorded a minimum of 12 out of 14 
consecutive days of diary data after a successful fitting (i.e. on their Test Diary), and having 
demonstrated at least a  50% reduction in the average number of FI epi[INVESTIGATOR_713606] 4 as compared to the Baseline Diary.  
Treatment Responder : An enrolled subject who demonstrates at least a 50% reduction in the 
average number of FI epi[INVESTIGATOR_713607] 
a responder for that time period. An enrolled subject must also have at least 10 out of 14 
consecutive days of recorded diary data on her Treatment Diary to be defined as  a responder for 
that time period.   
Treatment Non- Responder : An enrolled subject who does not demonstrate at least a  50% reduction 
in the average number of FI epi[INVESTIGATOR_713608], is a non -responder for that time period.  An enrolled subject with less than [ADDRESS_971439] PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 28 of 58 
 
   
 
consecutive days of recorded diary data on her Treatment Diary will also be classified as a non-
responder for that time period.  
3.3 Analysis Populations  
The Safety Population will include all subjects exposed to any part of the Eclipse System  during or 
after Visit 2 ( Initial Fitting Visit).  This will include all subjects who were unsuccessfully fitted, and 
screen failures. This will be the primary analysis population for all safety analyses.  
The Intent -to-Treat (ITT) Population will include all subjects  who are successfully fit with the Eclipse 
Insert , successfully complete Visit 4, and enter the Treatment Period.    
The Per -Protocol (PP) Population will include all subjects in the ITT population who complete Visit 5 
(Month 3 Visit), complete at least [ADDRESS_971440] no major  protocol deviations.  
3.4 Hypotheses  
The null hypothesis is that the proportion of treatment responders at 3 months is no more than 
40%, and the alternative hypothesis is that the proportion of treatment responders at 3 months is 
more than 40%:   
H0: π ≤ 0. 40  
 
HA: π > 0. 40 
3.5 Endpoints  
The primary effectiveness  endpoint is the proportion of tr eatment responders at the 3 month time 
point  in the ITT population.  
Secondary effectiveness  endpoints are:  
- The proportion of responders at the 3, [ADDRESS_971441]. Mark’s (Vaizey) Incontinence Severity 
Score , and FIQOL at the 3, 6, 9 and 12 month time points  
- PGI-I scores  at the 3, 6, 9 and 12 -month time points  
 
The safety endpoint is the safety of the device, as assessed by [CONTACT_713618]- related 
(Eclipse System) adverse events  and device –related serious adverse events , as adjudicated by 
[CONTACT_34164] (CEC) . 
 Subjects who are screen failures  will not be included in the effectiveness  endpoint analysis . 
However, their data will be reviewed to understand reasons for screen failure.  All subjects in whom 
the device was inserted, even if just for fitting, will be included in the safety analysis . For all screen 
fail subjects, t he Investigator  or designee will complete Case Report Forms related to the 
completed visits  and a Study Exit Form . 
3.[ADDRESS_971442] to evaluate whether the observed 
response rate is significantly larger than 40% after the first [ADDRESS_971443] PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 29 of 58 
 
   
 
The number and proportion of treatment responders, and its 95% confidence interval, using exact 
(Clopper -Pearson) confidence limits, will be presented .  A p -value for the one- sided upper -tail test 
of whether the proportion is significantly larger than 0.40, will also be presented.  
 
The null hypothesis will be rejected if a sufficient percentage of subjects exhibit treatment response at 
the 3 month time point.  
3.7 Secondary  Effectiveness Analyses 
The primary effectiveness  analysis will be repeated for the 3, 6 month and 12 month time points on 
the PP population.  
 Changes from baseline will be evaluated at the 3, 6, 9 and 12 month time points, for the f ollowin g 
effectiveness measures, also on the PP population:  
 
- St. Mark’s (Vaizey) Incontinence Severity Score  
- FIQOL  questionnaire subscales  
 
PGI-I scores  at 3, 6, 9 and 12 months (assessment not done at Baseline)   
3.8 Additional Analyses  
The change from baseline in the average (mean) number of FI epi[INVESTIGATOR_161594] , and percent 
change from baseline, will be evaluated at the 3, 6, and 12 month time points.  Negative values 
represent a decrease in the number of epi[INVESTIGATOR_1841] (i.e., improvement), w hile positive values represent 
an increase in the number of epi[INVESTIGATOR_1841].  
 
The change from baseline in the average (mean) number of FI days per week , and percent change 
from baseline, will be evaluated at the 3, 6, and 12 month time points.  Negative values represent a decrease in the number of days (i.e., improvement), while positive values represent an increase in 
the number of days.  
  
A cost analysis  comparing the Eclipse System  to other available therapi[INVESTIGATOR_713609]. 
This will be described in a  separate Statistical Analysis Plan.  
3.9 Subgroup Analyses  
The primary and secondary analys es will be repeated on the subgroups of < 65 years of age and   
≥ 65 years of age . 
3.10  Safety Analyses  
The number of overall adverse events  will be summarized using the Med ical Dictionary for 
Regulatory Activities (MedDRA) system organ class and preferred term  and listings will be reviewed 
at regular intervals by [CONTACT_15741] .  Device -related adverse events , and device -related serious adverse 
events  occurring at each time point w ill be summarized.  The CEC adjudicated AEs will be utilized in 
the safety endpoint analyses  
3.11 Power and Sample Size Considerations  
Power calculations were performed based on the primary effectiveness analysis, which tests 
whether the fraction of treatment responders is significantly greater than 0.40 (H 0: π ≤ 0.40  vs. H A: 
π > 0.40) using a one- sided exact binomial test, based on significance α = 0.025  and power 1 – β = 
0.90.  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 30 of 58 
 
   
 
Based on the LIFE study, we anticipate an 85.6% success rate among study completer s and 
conservatively estimate 21.3% dropout within 3 months, resulting in an estimated 67% response 
rate in this study.  With as few as 40  subjects in the ITT cohort, the study has ≥ 90% power to detect 
a response rate greater than 40%. Additional subjects,  up to the maximum of [ADDRESS_971444] dropout rate between the start of the Treatment Period and the 12 month 
visit to be 33%, yielding approximately 25 to 100 subjects completing 12 months of study 
participation .  In a 12 month study of non- surgical management of stress urinary incontinence the 
dropout rate over this same time period was approximately 36% .[ADDRESS_971445] who is exposed 
to the Eclipse System, including the Eclipse Insert , the Trial Insert or Sizers  (has any Eclipse System device 
inserted  into their vagina) will be included in the Safety Cohort and Safety Endpoint Analysis.  
Adverse event def initions are provided in Table 4.  Based  on clinical experience to date the expectation is 
a very low risk of serious or unanticipated device -related adverse events.   
Table 4. Adverse Event Categories  
Term  Definition  
Adverse 
event  (AE) Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs 
(including abnormal laboratory findings) in subjects, users or other persons, whether or not 
related to the investigational medical device. This definition incl udes events related to the 
study device and events related to any involved procedures.  
Serious 
adverse 
event  (SAE)  Any AE that  
• led to a death,  
• led to a serious deterioration in the health of the subject that:  
o resulted in a li fe-threatening illness or injury  
o resulted in a permanent impairment of a body structure or a body function  
o required hospi[INVESTIGATOR_1081]*  
o resulted in medical or surgical intervention to prevent permanent impairment to 
body structure or functio n, or to prevent one of the other outcomes (e.g. 
bronchospasm requiring treatment in an emergency room  
o led to fetal distress, fetal death, a congenit al abnormality, or birth defect  
 
Note that a planned hospi[INVESTIGATOR_272] a pre- existing condition, or a procedure required by [CONTACT_232415], without a serious deterioration in health, is not considered to be an SAE.  Note also 
that continuation of per manent disability (e.g.  failure of the Eclipse Insert to improve FI) is not considered 
an SA E. 
29 Richter, et al. non- surgical management o f stress urinary incontinence: ambulatory treatments for leakage associated with stress 
(ATLAS) trial. Clinical Trials 2007; 4: 92- 101. 
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page [ADDRESS_971446]  
(UADE) Any serious adverse effect on health or safety or any life -threatening problem or death caused 
by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, sever ity, or degree of incidence in the investigational plan or application (including a 
supplementary plan or application), or any other unanticipated serious problem associated 
with a device that relates to the rights, safety, or welfare of subjects.30  
* For purposes of defining a serious adverse event , hospi[INVESTIGATOR_713610] [ADDRESS_971447]’s usual activities  and 
requires a visit to a healthcare practitioner.  
Severe  The AE causes considerable interference with the subject’s usual activities; may be 
incapacitating and may require hospi[INVESTIGATOR_11298].  
4.[ADDRESS_971448].  
30 21 CFR 812.3(s)   
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page [ADDRESS_971449] the 
MedDRA coding dictionary for consistency , which will be described in detail  in the Data 
Management Plan.   
4.3.2  Clinical Events Committee  
A Clinical Events Committee (CEC), comprised of a Medical Monitor and a CEC Chair , will be 
responsible for the safety oversight of the Trial. The members will be  licensed and board certified 
physicians  with experience in female pelvic medicine and reconstructive surgery, including 
Urogynecology and Obstetrics and Gynecology. They will have  experience treating female fecal 
incontinence and with the functional mechanism of the Eclipse System. Experience as a PI [INVESTIGATOR_54720]-
Investigator in one or more previous multi -center FI trials is also a pre- requisite. However, they will 
not be affiliat ed with an enrolling site in the LIBERATE Trial. Additionally, the CEC members are 
required to declare any/all conflicts of interest to the Sponsor (as they arise) throughout the duration of the trial.  
4.3.3  CEC Adjudication of AEs  
The CEC Medical M onitor will review listings of all Sponsor -coded AEs at regular intervals to 
determine if any clarifications or coding changes are required, or if any additional information is needed in order to make a determination regarding  the relationship of an AE to any of the Eclipse 
System devices.  All device -related Serious AEs (SAEs)  and Unanticipated Adverse Device Effects 
(UADE s) will be reviewed by [CONTACT_3433] e CEC C hair in a timely manner ; all other AEs will be reviewed at 
monthly and quarterly meetings, as per the CE C Charter.  
A summary of all AEs will be provided to the CEC C hair for approval prior to results being utilized 
in the safety endpoint analyses . 
4.3.4  SAE Reporting  
All serious adverse event s (SAEs ) must be reported to the Sponsor within [ADDRESS_971450] for Medical Monitor review and Clinical 
Events Committee adjudication .  
The Sponsor will review all AEs suspected of being an SAE per Table 4 and will ensure any 
necessary reporting of the event(s) to investigators and reviewing IRBs as necessary.  
4.3.5  UADE Reporting  
Unanticipated adverse device effects (UADEs)  must be reported to the Sponsor within [ADDRESS_971451] (21 CFR 812.46(b)) and will ensure the necessary reporting of the event(s) to investigators and reviewing IRBs within [ADDRESS_971452] (21 CFR 812.46(b)(2)).   The Sponsor will only resume the investigation after obtai ning 
IRB, and if necessary, FDA approval (21 CFR 812.150(c )). 
5 Study Management  
Pelvalon , Inc. is the S ponsor of this clinical investigational plan.  T he LIBERATE study is proposed by [CONTACT_713641] a non- significant risk (NSR) study  (see Section 5.2.1) .  Investigational device exemption (IDE) 
approval from US FDA is not required for an NSR study  provided that the reviewing IRBs agree with the 
NSR designation.  NSR studies follow the abbreviated requirements listed in 21 CFR 812.231.  These 
requirements are s ummarized in Table 7 and described in more detail below.  
Table 7. Abbreviated Requirements for NSR Device Investigations  
Labeling per 21 CFR 812.5  
IRB approval with NSR determination  
Informed consent per 21 CFR 50  
Study Monitoring per 21 CFR 812.46  
Investigator Recordkeepi[INVESTIGATOR_713611] 21 CFR 812.140 (a) (3) (i)  
Sponsor Recordkeepi[INVESTIGATOR_713611] 21 CFR 812.140(b) (4) and (5)  
Investigator Reports required per 21 CFR 812.150 (a) (1), (2), (5), and (7)  
Sponsor Reports required per 21 CFR 812.150(b)(1) -(3), (5)- (10) 
Prohibition against promotion per 21 CFR 812.7  
5.1 Investigational Device Labeling 
As per 21 CFR 812.5, t he study device packaging includes a label with all required elements, 
including the statement: “CAUTION –  Investigational device.  Limited by [CONTACT_120905].”  In addition, the IFU describes all relevant contraindications, hazards, adverse 
events, interfering substances, warnings, and/or precautions.  
5.[ADDRESS_971453] be approved by [CONTACT_104489]’s IRB before the 
investigator may enroll subjects.  
This study is proposed as a non- significant risk (NSR) clinical study with r egulatory oversight  
managed by [CONTACT_713642]. Refer to the Sponsor’s Statement 
of Non- Significant Risk below in Section 5.2.1.   
5.2.1  Sponsor S tatement of Non -significant Risk  
Requirements for NSR studies are described by [CONTACT_13632] 21 CFR 812 and a corresponding 
guidance document .32 Devices are categorized as either “significant risk” or “non- significant risk.”  
A device is classified as non- significant risk if it does not meet the criteria of si gnificant risk as 
defined  below:  
According to 21CFR§812.3(m)  Significant risk device  means an investigational device that:  
31 http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=812&showFR=[ADDRESS_971454] PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 34 of 58 
                                                       
 
   
 
 (1) Is intended as an implant and presents a potential for serious risk to the health, safety, or 
welfare of a subject;  
(2) Is purported or represented to be for a use in supporting or sustaining human life and 
presents a potential for serious risk to the health, safety, or welfare of a subject;  
(3) Is for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise pr eventing impairment of human health and presents a potential for serious risk 
to the health, safety, or welfare of a subject; or  
(4) Otherwise presents a potential for serious risk to the health, safety, or welfare of a 
subject.  
 
Pelvalon  believes the Eclipse™ System  does not meet any of the above criteria, and is therefore a 
non-significant risk device.  Referencing 21CFR§812.3(m) above:  
(1) The Eclipse System  is not an implant.  It can be rapi[INVESTIGATOR_713612].    
(2) The insert  does not support or sustain human life.  
(3) The insert, in this application, is  not of substantial importance in diagnosing, curing, 
mitigating or treating disease. While it may be of substantial importance in  preventing 
impairment of human health by [CONTACT_713643], based on clinical evidence 
from several prior studies, it does not present a potential for serious risk to the health, safety, 
or welfare of the subject.  
(4) The study design does not introduce any procedures which are experimental.  Vaginal 
inserts such as diaphragms and pessaries are commonly used for a range of gynecologic 
and female health conditions.  Furthermore, the insert may be removed either by [CONTACT_713644].   
 
As with all prior Pelvalon studies, this study is proposed as a non- significant risk (NSR) clinical study . 
As detailed in Section 1.6  “Prior Investigations” , previous studies of the Eclipse System were granted 
NSR status  by [CONTACT_713645] . Also, FDA is aware of the NSR status of the prior studies 
and did not disagree with that designation. As a non- significant risk study, this study does not require 
submission and approval of an investigational device exemption (IDE) from FDA.  
5.3 Informed Conse nt 
Investigators will use a study -specific informed consent form which is consistent with regulatory 
requirements in 21 CFR 50, and will be approved by [CONTACT_78709].  The consent 
form template, found in Appendix 1  should be used as a template for each participating site’s 
consent.  The final consent form must be reviewed by [CONTACT_713646] , and a copy of the IRB approved version must be provided to the Sponsor prior to use 
in the study . 
5.[ADDRESS_971455] PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 35 of 58 
 
   
 
5.5 Recordkeepi[INVESTIGATOR_713613] 7 for 21 CFR  812.140(a) (3)(i):  
 
(3) Records of each subject's case history and exposure to the device. Case histories include the 
case report forms and supporting data including, for example, signed and dated consent forms and medical records including, for example, progress notes of the physician, the 
individual's hospi[INVESTIGATOR_3853](s), and the nurses' notes. Such records shall include:  
i. Documents evidencing informed consent and, for any use of a device by [CONTACT_713647], any written concurrence of a licensed 
physician and a brief description of the circumstances justifying the failure to obtain 
informed consent. The case history for each individual shall document that informed consent was obtained prior to participation in the study.  
 The Sponsor will maintain  the following records as required per  812.140(b) (4) and (5) : 
 
(4) The following records, consolidated in one location and available for FDA inspection and 
copying:  
- The name [CONTACT_29774] . 
- A brief explanation of why the device is not a significant risk device.  
- The name [CONTACT_29775] . 
- The name [CONTACT_29776].  
- A statement of the extent to which the good manufacturing practice regulation in 21 
CFR P art 820 will be followed in manufacturing the device.   
a. Any other information required by [CONTACT_8415].  
(5) Records concerning adverse device effects (whether anticipated or unanticipated) and complaints . 
5.5.[ADDRESS_971456] Retention  
Investigators and S ponsor shall maintain stu dy records for a period of 2 years after the latter of the 
following two dates: The date on which the investigation is terminated or completed, or the date 
that records are no longer required for purposes of supporting FDA marketing approval, or such 
longer period as required by [CONTACT_1289] . 
5.6 Reports  
The investigator will prepare and submit the following complete, accurate, and timely reports  as 
required per 812.150( a)(1) (2) (5) and (7) :  
 (1) Unanticipated adverse device effects. An investigator shall  submit to the sponsor and to the 
reviewing IRB a report of any unanticipated adverse device effect occurring during an 
investigation as soon as possible, but in no event later than [ADDRESS_971457].  
(2) Withdrawal of IRB approval. An investigator shall report to the sponsor, within 5 working days, a 
withdrawal of approval by [CONTACT_29752]'s part of an investigation.  
(5) Informed consent. If an investigator uses a device without obtaining informed consent, the 
investigator shall report such use to the sponsor and the reviewing IRB within 5 working days 
after the use occurs.  
(7) Other. An investigator shall, upon request by a reviewing IRB or FDA, provide accurate, 
complete, and current information about any aspect of the investigation.  
 
The sponsor shall prepare and submit the following complete, accurate, and timely reports  as 
required per 812.150(b)(1) -(3) and (5) -(10): 
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 36 of 58 
 
   
 
 
(1) Unanticipated adverse device effects. A sponsor who conducts an evaluation of  an unanticipated 
adverse device effect under 812.46(b) shall report the results of such evaluation to FDA and to 
all reviewing IRB's and participating investigators within [ADDRESS_971458] as FDA requests.  
(2) Withdrawal of IRB approval. A sponsor shall notify FDA and all reviewing IRB's and participating investigators of any withdrawal of approval of an investigation or a par t of an investigation by a 
reviewing IRB within 5 working days after receipt of the withdrawal of approval.  
(3) Withdrawal of FDA approval. A sponsor shall notify all reviewing IRB's and participating investigators of any withdrawal of FDA approval of the investigation, and shall do so within 5 
working days after receipt of notice of the withdrawal of approval.  
(5) Progress reports. At regular intervals, and at least yearly, a sponsor shall submit progress reports 
to all reviewing IRB's.  
(6) Recall and device disposit ion. A sponsor shall notify FDA and all reviewing IRB's of any request 
that an investigator return, repair, or otherwise dispose of any units of a device. Such notice shall occur within [ADDRESS_971459] was made.  
(7) Final report. In the case of a device that is not a significant risk device, the sponsor shall submit a final report to all reviewing IRB's within 6 months after termination or completion.  
(8) Informed consent. A sponsor shall submit to FDA a copy of any report by [CONTACT_523185] (a)(5) of this section of use of a device without obtaining informed consent, within 5 
working days of receipt of notice of such use.  
(9) Significant risk device determinations. If an IRB determines that a device is a significant risk 
device, and the sponsor had proposed that the IRB consider the device not to be a significant 
risk device, the sponsor shall submit to FDA a report of the IRB's determination within [ADDRESS_971460] learns  of the IRB's determination.  
(10) Other. A sponsor shall, upon request by a reviewing IRB or FDA, provide accurate, complete, 
and current information about any aspect of the investigation.  
5.7 Additional Investigator Responsibilities  
The site Principal Investigator (PI) is  responsible for the entire oversight and day-to-day conduct of 
the investigation and for ensuring that the investigation is conducted according to all signed 
agreements, the Clinical Investigational Plan, all applicable regulatory requi rements  and the 
principles embodied within the Declaration of Helsinki, and any conditions of approval imposed by 
[CONTACT_1201].  The site PI [INVESTIGATOR_713614] s, and for 
protecting the rights, safety and we lfare of subjects under the investigator’s care and for obtaining 
informed consent in accordance with 21 CFR Part 50.   
Additional r esponsibilities of the Investigator include, but are not limited to:  
 
• Maintain ing records of receipt, use or disposition of a device that relate to:  
- The type and quantity of the device, the dates of its receipt, and the lot number.  
- The names of all persons who received, used, or disposed of each device.  
- Why and how many units of the device are returned to the sponsor, or are otherwise 
disposed of.  
• Maintain ing subjects records of all relevant observations, including adverse device effects 
(whether anticipated or unanticipated), information and data on the condition of each subject upon entering, and during the course of, the investigation, including information about 
relevant previous medical history and the results of all diagnostic tests.  
• Maintaining records of dates  and reasons for each deviation from the protocol.  
• Ensuring that IRB approval is obtained prior the participation of a subject in a clinical trial.  
Such participation includes obtaining written informed consent . 
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 37 of 58 
 
   
 
• Ensuring that the Investigational device is used only under the supervision of an appropriately 
trained and qualified clinician.  
• Returning or disposing of the study supplies at the Sponsor’s written request . 
• Ensuring that all personnel assisting with the clinical trial are adequately informed and understand their trial -related duties and functions . 
 
Each site should  identify a study coordinator for this study.  Working with,  and under the authority of 
the site PI, the study coordinator assures that all study requirements are fulfilled, and is the contact 
[CONTACT_640141].  
 
Each Investigator must  allow direct access to source data/documents for trial r elated monitoring, 
audit, IRB  review and FDA  inspection, if needed.  Also, the investigator must  allow auditing of their 
clinical investigational procedure(s).  
5.7.1  Device Storage and Accountability  
The investigational Ecl ipse System components  will be stored at room temperature at the 
Investigational Site in a secure location with access limited to study personnel .  Any unused devices 
will be returned to the Sponsor at the completion of the investigational site’s participation in the 
study.  Sponsor may request used Trial Inserts (used during the screening period) to be returned 
to Pelvalon. All used Eclipse Inserts (used during the treatment period) must be returned to the 
Sponsor at the termination of a subject’s participation. All used Inserts must be returned using 
biohazard packaging materials and labels supplied by [CONTACT_1034], or disposed of at the site at the 
direction of the Sponsor.  The Investigator must maintain records of the receipt and disposition of 
all devices.  A record of the devices  used  by [CONTACT_713648]’s 
record (CRF and source document ).  
5.7.[ADDRESS_971461] Non -conformities and/ or User Feedback  
The site is responsible for returning used devices (considered bio- hazardous materials) or unused 
devices that are either non -conforming, related to a potential product malfunction,  related to an 
SAE, or at the direction of the Sponsor, in order to facilitate any necessary product investigations . 
The Sponsor will provide written instructions for reporting of the non- conformity and/or user 
feedback, and all necessary  materials , including biohazard labels, required for returning these 
devices to the Sponsor . The site is expected to cooperate with the Sponsor to gather all relevant 
information in any inves tigations initiated as a result  of a non- conformity or user feedback report.  
5.7.[ADDRESS_971462] requirements are described above in Sections  5.5 and 5.6.  In addition, the 
investigator will  maintain original  source documents from which study -related data are derived, 
which include, but are not limited to:  
 
• Clinic progress notes recording subject’s medical history and medications  
• Medical records regarding AEs, including treatment and clinical outcome  
• Records of non- study related assessments or interventions, such as r esults of diagnostic 
tests, and any hospi[INVESTIGATOR_602]  
• Notes of phone calls and/or correspondence indicating investigational site’s  attempts to follow 
study subjects at the required follow -up visits until subject’s participation in the study is 
complete or terminated 
• Records relating to subject  death (e.g., death certificate, autopsy report/terminal medical 
records)  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 38 of 58 
 
   
 
5.8 Sponsor Responsibilities  
Pelvalon , Inc. is the manufacturer of the Eclipse System  and S ponsor of this study.  The S ponsor’s 
recordkeepi[INVESTIGATOR_713615] 21 CFR 812 are described in Section s 5.5 and 5.6.  
Additional responsibilities include site  qualification, site initiation and training, interim monitoring, and 
close out  of the study at participating sites . 
5.8.1  Site Qualification  
The Sponsor will review investigator qualifications for study participation by [CONTACT_713649] , 
as needed to determine site suitability for the study .  Sites will be evaluated to confirm adequate 
trained and experienced staff (in general  clinical research procedures and the therapeutic area) , 
including a designated study coordinator , and facilities to perform the s tudy according to the 
requirements of the protocol , as well as an adequate subject population.  
5.8.2  Site Initiation and Training  
Prior to enrolling any subjects a site initiation visit will be conducted to confirm the site continues to 
be able to meet the requ irements of the trial.  All investigators , device fitters  and study coordinators 
will undergo study -specific training prior to or during a Site Initiation Visit , to review the 
Investigator/site responsibilities  and requirements for the study . These include but are not limited 
to: 
 
• Device use training for clinicians who are fitting the device  
• Instructions for Use (IFU)  
• Subject  Use and Care Instructions  
• Clinical Investigational Plan (CIP)  
• Regulatory files  
• Consenting procedures , including the protection of subject  confidentiality  
• IRB reporting requirements  
• Data entry procedures and guidelines, which may include training in use of an Electronic 
Data Capture (EDC) system 
• Device accountability and storage procedures  
 
Site personnel training will be documented and all study training records will be maintained by [CONTACT_429].  
5.8.[ADDRESS_971463] been met : 
 
• CV and medical license is on file for PI   
• Clinical Investigational Plan (CIP) Signature [CONTACT_3490], signed by [CONTACT_978], is on file  
• Signed Investigator Agreement  is on file for PI  
• The IRB approval of the investigational plan  and informed consent form  are on file  
• Clinical Trial Agreement  between the Site and the Sponsor is fully executed  
• Site initiation and training visit is compl eted and the required training records are on file  
 
Under no circumstances should a site begin recruiting subjects for the study without written 
authorization to do so from the IRB and the Sponsor.  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page [ADDRESS_971464] 2 to 5 subjects  are enrolled 
in the study.  The frequency of subsequent visits will be dependent upon the rate of enrollment and 
site performance on previous monitoring visits.  
Monitoring of the study will be a continuous process conducted in accordance with 21 CFR 812.46 
and applicable Sponsor procedures.  Monitoring will be performed by [CONTACT_713650], or designees (contract CRAs) .  The monitors w ill follow the procedures 
described within the Monitoring Plan, briefly summarized below:  
• Monitors will be qualified by [CONTACT_713651].  
• Remote monitoring of electronic Case Report Forms will occur on an ongoing basis as part of the routine data review and data management activities. Queries will be issued, reviewed and 
resolved within the electronic data capture (EDC) system on an ongoing basis. Remote 
monitoring may also be done via review of faxed/scanned diaries, questionnaires, CRFs, and 
de-identified source documents.  
• Onsite monitoring of source documentation, the regulatory binder and device accountability 
records will occur at regular intervals as subject enrollment and data volume dictates, according 
to the Monitoring Plan, but no less than once during the trial and again at the end of the trial.  
• Monitors will ensure the appropriate reporting of protocol deviations, AEs, SAEs, and UADEs 
within the case report forms, to the Sponsor and to the governing IRB.  
• Monitors will facilitate the requests for, and transmission of, de- identified source documents 
from the site to the Sponsor, as requested for Medical Monitor review and adjudication of 
Adverse Events or to support investigations of product non- conformance or complaints.  
• If there are significant non -compliance issues at a site, including lack of adherence to the 
protocol or applicable regulatory requirements, the issues will be discussed with the 
Investigator and study coordinator and the sit e will be instructed on how to regain compliance.  
• Noncompliance with the signed agreement, the investigational plan, or other applicable regulatory requirements, will be communicated by [CONTACT_713652]’s study 
management team, and will be documented in the monitoring report and the follow up letter. The monitor and the Sponsor’s study management team will work with the site to secure compliance through corrective and preventive action (CAPA) planning and documentation, as necessary . 
• In cases of s erious or repeated nonconformance the Sponsor  may either temporarily or 
permanently discontinue shipments of the investigational devices  to the site, or temporarily or 
permanently put the site “on hold” for screening and enrolling new subjects. All subject s 
currently enrolled will continue to be followed as per the protocol until they can be appropriately exited from the study.  
• The Sponsor will also ensure that investigators return any unused devices, unless this action 
would jeopardize the rights, safety,  or welfare of a subject.  
5.8.[ADDRESS_971465] a remote close out visit will be transmitted  in writing to the applicable site(s) and may 
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page [ADDRESS_971466] been previously monitored.  The 
purpose of the Close -out Visit  is to: 
• Reconcile all outstanding data queries  
• Review the records retention requirements for the study  as per Section 5.5.1  
• Arran ge for the return of all study materials to the Sponsor  
• Review the final IRB requirements for the study  
5.[ADDRESS_971467]’s unique identifier and name.  The 
investigator bears responsibility for keepi[INVESTIGATOR_147345].  This list will not be provided to the 
study Sponsor and is only to be used at the study center.  
Monitors and auditors will have access to the study subject list and other personally identifying 
information of study subjects to ensure that data reported in the CRF corresponds to the person who 
signed the ICF and the information contained in the original source documents.  Such personal 
identifying information may include, but is not limited to the subject’s name, address, date of birth, 
gender, race and medical record number.   
NOTE: The subject’s name, medical record number or address will NOT be recorded in the monitor’s 
visit report or the database; demographic data that may be recorded include date of birth, race, and 
gender.   
Source documents copi[INVESTIGATOR_713616]’s unique identifier in order to protect subject confidentiality.  
The data collected about each subject, and the results of this study, belong to the Sponsor and may 
be used for business purposes such as in publications, marketing materials, or regulatory submissions.  An IRB- approved HIPAA authorization is required to be signed by [CONTACT_713653] t heir medical records monitored.   
5.[ADDRESS_971468] ronic data capture (EDC) system will be validated and verified as  21 
CFR Part 11 compliant.   Sites will be trained in completion of CRFs and the use of the EDC system  
prior to being issued access to the system .   
The Sponsor is responsible for the design and user acceptance testing of the database, and for 
routine data review, monitoring (remotely and onsite) , and query resolution.  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page [ADDRESS_971469] with the study protocol.  All protocol deviations will be documented in the site files, 
and on the appropriate case report form( s).   
The investigator should notify the Sponsor and the IRB immediately if any protocol deviation was 
necessary in order  to protect the life or physical well -being of a subject in an emergency. All protocol 
deviations should be reported to the governing IRB accor ding to the IRB’s requirements.   
5.13 Study Suspension or Early Termination 
The study may be discontinued at the discretion of the Sponsor either at an individual site or at all 
sites for reasons including, but not limited to, the following:  
• Occurrence of unexpected adverse events  or unanticipated adverse device effects  
• New scientific information that shows that the study is no longer valid or necessary  
• Insufficient recruitment of subjects  
• Persistent non- compliance with the protocol  
• Persistent non- compliance wit h IRB or regulatory requirements  
• Business reasons  
 
If the study is discontinued or suspended prematurely, the S ponsor will promptly notify  the following 
in writing of the termination or suspension and the reason(s) for it:  
• All clinical investigator(s)/inve stigational center(s)  
• All governing central IRBs  
 
If the study is discontinued or suspended prematurely, the Investigator(s) will promptly notify the 
following in writing of the termination or suspension and the reason(s) for it:  
• Their governing l ocal IRB s 
• The subjects and/or their primary care physicians if deemed necessary  by [CONTACT_713654]    
5.[ADDRESS_971470]  are minimized b y use under 
the care and instruction of the investigator , regular study visits  and because subjects may remove the 
device at any time as  needed.   Subjects may experience a change in bowel or urinary habits while using 
the device.  Common side effects relat ed to poor hygiene with the use of vaginal devices are malodorous 
odor, vaginal discharge and itching.  Subjects will be advised to maintain proper hygiene, and on the use 
and care of the Eclipse System ( Appendix 9). 
Anticipated risks associated with the use of the Eclipse System , as seen in the previous clinical evaluations,  
include : 
• Pelvic Crampi[INVESTIGATOR_713617]  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 42 of 58 
 
   
 
• Pelvic Pain  
• Vaginal Erythema / Petechiae  
• Vaginal Discharge  
• Vaginal Abrasion  
• Vaginal Bleeding  
• Vaginal Spotting  
• Vaginal Ecchymosis or Bruising  
• Vaginal Irritation  
• Yeast Infection (Candidiasis)  
• Lower Urinary Tract Infection  
• Urinary Incontinence  
• Urinary Urgency / Frequency  
• Difficulty with Urinary Voiding  
• Difficulty with Stool Evacuation  
 
Refer to the IFU ( Appendix 8 ) for a li st of warnings and precautions.  
It is possible that a ny of these risks or discomforts may occur with greater frequency or severity than 
previously reported.  It is also possible that there are risks that are unknown at this time. As detailed in the 
background section, previo us clinical evaluatio ns of the Eclipse  System in over [ADDRESS_971471]   
 
 
Section  Description of Change  Rev C – 10 Dec 2015  Rev D – 09 Feb 2017 
Protocol 
Synopsis  Clarified that enrollment may 
be up to 150 subjects.  150 treatment -eligible subjects will be 
enrolled into the 12 month Treatment 
Period at up to 15 clinical sites in the 
[LOCATION_002]  Up to 150 treatment -eligible subjects may 
be enrolled into the 12 month Treatment 
Period at up to 15 clinical sites in the United 
States  
Table of 
Contents  Updated page numbers.  NA NA 
2.2 Target 
Population  Clarified that enrollment may 
be up to 150 subjects.  
Removed statement that half 
of subjects enrolled will be 65 
or older . It is anticipated that up to 625  subjects 
may need to be screened and consented 
to yield 150 subjects entering the 
Treatment Period for the effectiveness  
analysis.  
Safety will be evaluated based on all 
subjects who undergo fitting with the 
Eclipse System. Recruitment will be 
managed to ensure approximately one 
half of the subjects who enter the 
Treatment Period are age 65 and older.  It is anticipated that up to 625 subjects may 
need to be screened and consented to yield 
up to 150 subjects entering the Treatment 
Period for the effectiveness  analysis.  
Safety will be evaluated based on all 
subjects who undergo fitting with the Eclipse System.  
2.3 Recruitment  Clarified that enrollment may 
be stopped or paused at any 
time by [CONTACT_1034].  Revised 
individual site enrollment 
contribution levels from a 
number cap to a percent of 
total launched. Removed 
statement that enrollment 
may be restricted by [CONTACT_26423]-
group.  Each site is expected to enroll a minimum 
of 10 and a maximum of 30 treatment -
eligible subjec ts...Enrollment is 
competitive until overall enrollment target 
is reached, and recruitment may be 
restricted by [CONTACT_26423]-  groups to ensure 
approximately one half of the subjects 
entering the Treatment Period are <65 
years of age and one half are >65 years 
of age. Each site is expected to contribute 
approximately 7- 25% of the total treatment -
eligible subjects...Enrollment is competitive 
until overall enrollment target is reached or 
study termination by [CONTACT_1034].  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE PROPERTY OF  PELVALON, INC . NEITHER  THIS 
DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  
PELVALON, INC.  
 Page 45 of 58 
 
   
Section  Description of Change  Rev C – 10 Dec 2015  Rev D – [ADDRESS_971472] potential interim 
analyses.  The null hypothesis will be rejected if 
72/150 of subjects exhibit treatment 
response at the 3 month time point.  The null hypothesis will be rejected if a 
sufficient percentage of subjects exhibit 
treatment response at the 3 month time point.  
3.11 Power 
and Sample 
Size 
Considerations  Added in ranges based on 
revised enrollment and power 
estimates . Removed power 
estimates for non- primary 
endpoints.  Based on the LIFE study, we anticipate 
an 85.6% success rate among study 
completers and conservatively estimate 
21.3% dropout within 3 months, resulting 
in an estimated 67% response rate in this 
study.  With 150 subjects in the ITT 
cohort, the study has >90% power to 
detect a response rate greater than 40%.   
Withdrawal from the study during the 
Screening Period is estimated to be quite 
high due to the baseline diary completion 
and device fitting requirements. Subjects 
who are successfully fit with the Ecli pse 
System and successfully complete the 
Screening Period will be eligible for 
treatment. Therefore, an estimated [ADDRESS_971473] dropout rate 
between the start of the Treatment Period 
and the 12 month visit to be 33%, yielding 
100 subjects completing 12 months of 
study participation.  In a 12 month study 
of non- surgical management of stress 
urinary incontinence the dropout r ate over 
this same time period was approximately Based on the LIFE study, we anticipate an 
85.6% success rate among study 
completers and conservatively estimate 
21.3% dropout within 3 months, resulting in 
an estimated 67% response rate in this 
study.  With as few as 40 subjects in the ITT 
cohort, the study has ≥90% power to detect 
a response rate greater than 40%. 
Additional subjects, up to the maximum of 
[ADDRESS_971474] dropout rate 
between the start of the Treatment Period 
and the 12 month visit to be 33%, yielding 
approximately  [ADDRESS_971475] PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  
PELVALON, INC.  
 Page 46 of 58 
 
   
Section  Description of Change  Rev C – 10 Dec 2015  Rev D – 09 Feb 2017 
36%.33 The study has a 90% power to 
detect a response rate greater than 40% 
at 12 months . management of stress urinary incontinence 
the dropout rate over this same time period 
was approximately  36%. 
NA Minor clarifications and edits 
to spelling throughout 
Protocol.  NA NA 
 
 
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE PROPERTY OF  PELVALON, INC . NEITHER THIS 
DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  
PELVALON, INC.  
 Page [ADDRESS_971476] PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 48 of 58 
 
   
Appendix 1 – Informed Consent Form Template  
[Incorporated by [CONTACT_713655]]  
  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETA RY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 49 of 58 
 
   
Appendix 2 – FI Epi[INVESTIGATOR_713580] 
[Incorporated by [CONTACT_713655]]  
 
  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETA RY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 50 of 58 
 
   
Appendix 3 – FIQOL  Questionnaire  
[Incorporated by [CONTACT_713655]]  
 
  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETA RY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 51 of 58 
 
   
Appendix 4 – PGI-I Questionnaire 
[Incorporated by [CONTACT_713655]]  
 
  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETA RY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 52 of 58 
 
   
Appendix 5 – Patient Goal Questionnaire 
[Incorporated by [CONTACT_713655]]  
 
  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETA RY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 53 of 58 
 
   
Appendix 6 - Device Satisfaction Questionnaire  
[Incorporated by [CONTACT_713655]]  
 
  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETA RY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 54 of 58 
 
   
Appendix 7 – FI Information Brochure  
[Incorporated by [CONTACT_713655]]  
 
  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETA RY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 55 of 58 
 
   
 
Appendix 8 – Eclipse System Instructions for Use  
[Incorporated by [CONTACT_713655]]  
 
  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETA RY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 56 of 58 
 
   
Appendix 9 – Eclipse System Use and Care Instructions  for LIBERATE Study Subjects  
[Incorporated by [CONTACT_713655]]  
 
  
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETA RY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 57 of 58 
 
   
Appendix 10 –  Cost Utilization Survey  
[Incorporated by [CONTACT_713655]]  
 
CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETA RY INFORMATION THAT IS THE 
PROPERTY OF  PELVALON, INC . NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF  PELVALON, INC.  
 Page 58 of 58 
 